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Photoreceptors are specialized neurons that form the first-order of the visual pathway. 
The retina displays prodigious energy demands which have been largely attributed to 
significant aerobic glycolysis by photoreceptors.  Retinal degenerative diseases such as 
Retinitis Pigmentosa (RP), Age-related Macular Degeneration and Diabetic Retinopathy 
which involve the degeneration of photoreceptors are thought to involve a 
pathophysiological component of cellular energy deficiency. Hence, therapies 
addressing this component to conserve neurons, termed bioenergetic neuroprotection 
may be viable options to combat these diseases. RP is a collection of heterogeneous 
hereditary retinal dystrophies that are marked by genetic rod mutations leading to rod 
loss followed by secondary cone loss. There has been speculation behind the 
mechanisms of cone loss although more recently a bioenergetic dysfunction has been 
proposed. There is currently no viable treatment for RP although preventing cone loss 
would be a clinically significant therapeutic outcome and medical breakthrough. 
Photobiomodulation (PBM) which refers to irradiation of tissue with 630-1000nm light, 
is known to increase cellular energy, decrease oxidative stress and inflammation. Hence, 
PBM would be a novel bioenergetics neuroprotective therapy for retinal degenerative 
disease including RP. Past studies have examined light-emitting diode (LED) based 
PBM on retina however there is concern of scattering and filtering of incoherent light. 
Moreover, there is no consensus on optimal treatment parameters. Therefore, the 
overarching aims of my thesis were to 1) investigate safe and optimal dosages of PBM 
laser in normal rat retinae and 2) examine the neuroprotective efficacy of PBM laser in a 
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retinal degeneration rodent model. The first experiment assessed the safety of PBM laser 
at irradiance doses 25, 100, 500 mW/cm2 and at a duration 90 seconds in pigmented and 
albino rats. Structural and functional parameters were measured through electro-
retinogram, spectral domain optical coherence tomography, fluorescein angiography and 
histological evaluation. PBM laser was safe at low and medium irradiance doses 
however there was occasional focal structural damage only in pigmented rats exposed to 
500 mW/cm2 irradiance. There were otherwise no functional changes and albino rats 
were unaffected. The findings in this study helped decide suitable irradiance dosages for 
the subsequent study. The second experiment examined the neuroprotection efficacy of 
PBM laser in the rd1 mice, a rapidly progressive autosomal RP rodent model. Mice were 
lasered twice weekly until P90 before their retinae were examined for cone survival 
through immunofluorescent staining. Cone function was examined through optokinetic 
assessment. We found significant cone neuroprotection in treated eyes that was 
supported by significant preservation of visual function. The current body of work 
should motivate further studies to explore the neuroprotective mechanisms of PBM and 
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1.1 Structure of the Retina 
The vertebrate retina is a light-sensitive tissue located at the posterior portion of the 
interior of the eye. It is predominantly a neuronal tissue, and the neural region comprises 
two synaptic layers alternating between three cellular layers. 
Structurally, there are generally recognized to be ten clearly identifiable layers of the 
retina (Figure 1.1). Starting from the most interior portion of this tissue, the layers are as 
follows: 
1. Inner limiting membrane (ILM), which is a basement membrane layer formed 
from astrocytes and the end feet of Müller cells. 
2. Nerve fibre layer (NFL) containing retinal ganglion cell axons. 
3. Ganglion cell layer (GCL) comprising of retinal ganglion cell bodies and 
displaced amacrine cells. 
4. Inner plexiform layer (IPL) which is a dense fibrillar zone composed of dendrites 
of ganglion, bipolar, horizontal and amacrine cells, and their synaptic inter-
connections. 
5. Inner nuclear layer (INL) encompassing cell bodies of bipolar, horizontal and 
amacrine cells as well as of Muller glial cells. 
6. Outer plexiform layer (OPL) containing synapses between photoreceptors, 
bipolar cells and horizontal cells. 




8. External limiting membrane (ELM) which separates the inner segment from the 
cell body of photoreceptors and which is made up of tight junctions between 
these cells and Muller cells. 
9. Photoreceptor segment layer which comprises the inner segments (IS) and outer 
segments (OS) of rod and cone photoreceptors. 
10. Retinal pigment epithelium (RPE) which is a monolayer of cuboidal cells that is 
adjacent to the choriocapillaris and which forms the outer blood retinal barrier. 
 
Figure 1.1: Light micrograph of a normal rat retinal section, stained with 
haematoxylin and eosin. ILM, inner limiting membrane; NFL, nerve fiber layer; GCL, 
ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer 
plexiform layer; ONL, outer nuclear layer; ELM, external limiting membrane; IS, 





Photoreceptors are specialized retinal neurons that contribute to the initial steps in vision 
by converting light into electrical signals to be interpreted by the brain: a process known 
as phototransduction. There are three types of photoreceptors in the vertebrate retina: 
rods, cones (known as the “classical photoreceptors”) and the intrinsically photo-
sensitive retinal ganglion cells.  
In human and non-human primates, rods comprise 95% of the classical photoreceptors 
and are located throughout the retina, except in the fovea and the blind-spot, but are 
concentrated in the periphery. In mice retinae, rods comprise of 97% of photoreceptors. 
These cells are responsible for mediating dim (scotopic) vision, and are sensitive to a 
single light photon. Cones on the other hand, which comprise the remaining 5% of the 
classical photoreceptors, are less sensitive to light, and are densely packed in the rod-
free area of the retina known as the fovea. They are responsible for bright-light 
(photopic) and colour vision. Intrinsically photo-sensitive retinal ganglion cells are a 
diverse collection of cells that contain the pigment melanopsin and are responsible for 
conveying ambient signals to higher brain centres.1,2 For the purposes of this thesis the 
term photoreceptor will refer only to the classical photoreceptors. 
 
1.2.1 Structure of photoreceptors 
General overview 
Structurally, photoreceptors have an elongated shape and are compartmentally organized 
into an outer segment (OS), inner segment (IS), cell body and synaptic region (Figure 
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1.2). The OS possesses photo-sensitive pigments that facilitate photon absorption and 
subsequent conversion to electrical signals to be interpreted by the brain, a process 
known as phototransduction.  
The inner segments contain the majority of the organelles including the endoplasmic 
reticulum, Golgi complex and mitochondria. Many ion channels are also present, on the 
plasma membrane, here. Separating the OS and IS is a cylindrical structure composed of 
doublet microtubules called the connecting cilium which may facilitate protein transport 
between the segments. The cell body holds the photoreceptor nucleus and is continuous 
with the inner segment (IS). The synaptic region comprises synaptic vesicles and ribbon 
synapses that connect to bipolar and horizontal cells at the outer plexiform layer (OPL).  
Rods and cones have notable architectural differences in the OS which may explain 
differences in their sensitivity and ability to respond to varying light intensities. 
 
Rod OS structure 
Rods have more elongated OS compared to cones, with the typical mammalian rod OS 
having a diameter of 1.2-2.0 µm and a length of 20-34 µm.3 2,4,5. Electron microscopy of 
the rod OS reveals stacks of disk membranes that are discontinuous with the plasma 
membrane unlike the cone OS, which are formed as membrane invaginations.  Within 
the disk membranes are abundant photo-sensitive units, based on the protein, rhodopsin, 
which absorb photons as part of the phototransduction cascade.6 Rhodopsin is composed 
of the chromophore 11-cis-retinal (Vitamin A derivative) and a light sensitive opsin 
subtype called scotopsin. Other prominent phototransduction proteins are the trimeric G-
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protein, transducin, made up of α, β and γ subunits, and phosphodiesterase (PDE6) 
which consists of the two sub-units PDE6A and PDE6B as well as two identical 
inhibitory sub-units of PDE6G. Within the rod OS plasma membrane is the cyclic 
nucleotide gated (CNG) channel consisting of three CNGA1 and one CNGB1 subunits. 
The CNG channel forms a complex with the Na+–Ca2+–K+ exchanger (NCKX1 or 
SLC24A1) on the OS plasma membrane and plays a vital role in hyperpolarization 
during phototransduction.7 Gene mutations related to phototransduction membrane 
proteins commonly result in retinal diseases. Mutations in the genes encoding arrestin, 
rhodopsin kinase or NCKX1 cause congenital stationary night blindness (CSNB) whilst 
gene mutations affecting rhodopsin, CNGA1, CNGB1, PDE6A or PD6B result in 
Retinitis Pigmentosa. 7 
 
Cone OS structure 
Cones have shorter OS than rods, with a typical length of 13 µm and diameter of 1.2 µm. 
The cone OS initially form evaginations that gradually develop into a series of discs 
which are continuous with the OS plasma membrane, tapering to form a cone-like 
shape.8 Similar to rods, the disk membranes house photopigments consisting of 11-cis-
retinal and light sensitive cone opsins called photopsins. In the primate retina, there are 
classically three classes of photopsins: S (OPN1SW), M (OPN1MW) and L (OPN1LW) 
with maximum absorbance within the visible spectrum wavelengths of 420-440 nm, 
530-545 nm and 558-565 nm respectively.9 There are differences in the composition of 
PDE6 and the CNG channel between rods and cones. The cone PDE6 is composed of 
two identical catalytic sub-units of PDE6C and two identical inhibitory sub-units of 
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Figure 1.2: Schematic diagram showing the generalized structure of both rod and 
cone photoreceptors. These cells are structurally similar and include an outer 
segment, connecting cilium, cell body, axon and synaptic region. The outer segment is 
made up of stacked disks of photopigments. The cilium is made up of a ring of doublet 
microtubules that forms a bridge between the outer and inner segment. The inner 
segment is composed of several organelles including the mitochondria, Golgi complex 
and endoplasmic reticulum.  The cell body houses the photoreceptor nucleus. The 
axon comprises nerve fibers that lead to the synaptic region which contains synaptic 





1.2.3 Phototransduction cascade 
The steps of the phototransduction cascade are similar in cones and rods. Upon exposure 
to light, the photopigment component 11-cis-retinal is photoisomerized to the all-trans-
retinal isomer which results in conformational change of the bound opsin. This causes 
the active opsin to bind to transducin, resulting in catalytic exchange of guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP) on the α sub-unit of transducin. 
This leads to the α-subunit of transducin to dissociate from its bound βγ subunits, 
thereby activating PDE6 which hydrolyses cyclic guanosine monophosphate (cGMP). 
The decrease in cGMP causes the closure of CNG channels, reduced cation influx and 
subsequent hyperpolarization. When the cell is in its hyperpolarized state, voltage-gated 
calcium channels close, culminating in decreased release of the neurotransmitter, 
glutamate, at the synaptic region.  
The resetting of the photoreceptor cell back to its dark-state occurs through a similarly 
discrete sequence of steps. In rods, activated rhodopsin becomes phosphorylated by 
enzymes such as G-protein coupled receptor kinase, protein kinase C or rhodopsin 
kinase, before being deactivated by binding to arrestin.12 The renewal of rhodopsin 
requires conversion of all-trans-retinal to 11-cis retinal which occurs in the visual cycle 
(outlined in the section below). Hydrolysis of GTP on the sub-unit of transducin results 
in PDE6 returning to its previous state. Activation of guanylate cyclase through 
guanylate-cyclase-activating proteins (GCAPs) results in restoration of cGMP levels.13 
This triggers the re-opening of CNG channels and the renewal of the photoreceptor to its 
dark, partially depolarized state. Whilst in this state, the influx of Na+ and Ca2+ through 




Figure 1.3: Phototransduction cascade: Light causes photoisomerization of 11-cis retinal to all-trans-retinal. This results in a conformational change of opsin 
and activation of transducin. The activated transducin then separates into the βγ subunit and GTP/α-subunit complex, the latter resulting in activation of 
PDE6 and hydrolysis of cGMP. The drop in cGMP results in closure of Cyclic Nucleotide gated channels and subsequent decreased sodium influx and 
potassium efflux. The cell membrane becomes hyperpolarized, resulting in closure of calcium channels. The decrease in intracellular calcium leads to 
decreased glutamate release at the synaptic region. 
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1.2.4 Visual cycle 
The visual cycle is the process by which 11-cis-retinal is regenerated from all-trans-
retinal. Following light exposure, all-trans-retinal is converted into all-trans-retinol by 
retinal dehydrogenase in the OS before being transported to the RPE by interstitial 
retinol-binding protein 3 (RBP3) .14,15 All-trans-retinol can also originate from the blood 
circulation, carried by serum retinol binding protein, before entering the RPE cell 
basolaterally through the STRA6 (Stimulated by retinoic acid 6) protein.16,17 Whilst in 
the RPE, all-trans-retinol is bound to cellular retinol binding protein and esterified to all-
trans-retinyl-ester in the presence of the catalyst lecithin retinol acyl transferase. All-
trans-retinyl-ester undergoes isomerization via the action of the enzyme retinoid 
isomerohydrolase (RPE65) to produce 11-cis-retinol which is subsequently converted by 
11-cis-retinol dehydrogenase to produce 11-cis-retinal. 11-cis-retinal is then transported 
by RBP3 to the OS where it combines with opsin to reform rhodopsin or cone opsin. 
The cycle is repeated following light exposure whereby the resulting all-trans-retinal is 
reconverted to its all-trans-retinol and cycled back to the RPE for reisomerization and 
oxidation.16 18  The comparatively faster regeneration rate of cone pigment has lead to 
the postulation of an alternative cone visual cycle separate from the RPE involving 
Müller cells.19 In vitro experiments of cultured chicken Müller cells demonstrate 
isomerization of all-trans-retinol to 11-cis-retinol which enact as a source for cone 
photopigment.20 Later experiments by Mata et al.21 reported the presence of all-trans 
retinol isomerase, 11-cis-retinyl-ester synthase and 11-cis-retinol dehydrogenase in 
cone-rich ground squirrel and chicken retinae that support the existence of a cone visual 
cycle revolving around Müller cells.  More recently, there has been data to support a 
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cone visual cycle in human and primate retinae.19 However, the exact mechanisms of the 
cone visual cycle are still poorly understood and remain a topic of research interest. 
 
1.2.5 Energy metabolism 
Photoreceptors are known to be highly metabolically active cells that constitute a 
significant portion of the retina’s energy consumption. The generation of adenosine 
trisphosphate (ATP), the essential form of intracellular energy transport in all lifeforms, 
is achieved through two pathways: glycolysis and oxidative phosphorylation. The major 
energy substrate in both pathways is glucose which is generally catabolised to pyruvate, 
where it enters the Krebs cycle to facilitate oxidative phosphorylation, in the presence of 
oxygen. When oxygen is scarce, pyruvate is shunted away from oxidative 
phosphorylation and is converted to lactate by the enzyme lactate dehydrogenase. 
Lactate derived from Müller cells has been identified as a possible energy substrate for 
photoreceptors; however, there is evidence that glucose is the preferred energy substrate 
when adequately available.22,23 Other bioenergy-related mediators known to be utilized 
or metabolised by photoreceptors include phosphocreatine and amino acids.24 Oxidative 
phosphorylation in the mitochondria is much more efficient than glycolysis, yielding up 
to 36 ATP molecules compared to 2 ATP molecules generated in glycolysis. 
Interestingly, the isolated retina produces abundant lactate despite the presence of 
oxygen, and displays similar metabolic characteristics to cancer cells - a phenomenon 
known as the Warburg effect or aerobic glycolysis.25 One postulation for this 
observation is that aerobic glycolysis allows for the production of metabolic 
intermediates for biosynthesis especially in the retina where there is immense turnover 
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of the photoreceptor outer segment.26,27 Noell et al.28 demonstrated that inhibition of 
glycolysis by iodoacetate resulted in decreased retinal and rod cell function measured by 
decreased electrical amplitudes on the electroretinogram (ERG). Additionally, 
Graymore observed a decrease of glycolysis by more than 50% in dystrophic rat retinae 
lacking photoreceptors compared to normal rat retinae.29,30 Moreover, Chertov 
demonstrated that glucose withdrawal leads to mitochondrial failure, ATP depletion and 
subsequent photoreceptor cell death in isolated mouse retinae.31  
The amount of energy utilized by the photoreceptor is dependent on the degree of light 
exposure. Greater energy is required in the dark to maintain ionic gradients, particularly, 
the pumping out excess Na+ via the Na+/K+ ATPase pump in the inner segment, creating 
the so-called “dark current”. In bright-light conditions, the outer segment uses energy 
mainly for phototransduction and light adaptation, with remaining energy used for the 
production, recycling and transportation of photopigments and neurotransmitters.24 In 
mouse rods, it is estimated that 1x108 molecules of ATP are used per second in the dark 
whilst only less than a quarter of this amount is utilized in light.32 
In darkness, the ATP expenditure of cones and rods is similar due to their analogous 
voltage-dependence and amplitude of the dark current. In bright light, cones have 
significantly greater ATP expenditure than rods, however, for several reasons: the 
turnover of transducin is at least twice as great; Na+ influx through cGMP-gated 
channels does not reduce more than half; higher depolarization rate in cones; and greater 
rhodopsin kinase activity.10,32   
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Comparatively, oxygen concentration and lactate formation in the inner retina remains 
consistent in light and dark, suggesting the inner retina’s metabolism is not influenced 
by differences in lighting conditions.33 
Energy deficiency has been attributed as a cause of degeneration of photoreceptors in 
inherited diseases including Retinitis Pigmentosa34,35 as well as acquired diseases such 
as age-related macular degeneration36,37, diabetic retinopathy 38 and central retinal 
artery/vein occlusion39,40. A form of intervention known as bioenergetic neuroprotection 
could specifically address this metabolic issue, thereby potentially preserving 
photoreceptors or slowing down their degeneration. 
1.3 Bioenergetic neuroprotection 
In the broadest sense, neuroprotection refers to the relative preservation of neurons 
following an insult. In a bioenergetic-based approach, neuroprotection aims to preserve 
damaged or threatened neurons by increasing the availability of the energy supply.41 The 
neuroprotective benefit of several bioenergetic agents has been observed in several 
animal models of neurological and ophthalmic diseases. Creatine, which may provide 
protection by metabolic energy buffering, has been found to be neuroprotective in 
Parkinson’s disease42, Huntington’s disease43-45, Amytrophic Lateral Sclerosis46, 
cerebral ischaemia47 and traumatic brain injury47,48. Nicotinamide, a precursor to 
nicotinamide adenine dinucleotide phosphate, has been successful in protecting against 
phototoxic49 and ischaemic retinal injury50 as well as cerebral excitotoxic injury as 
induced by the ionotropic glutamate receptor agonist, N-methyl-D-aspartate51. Moreover, 
ubiquinone has also found to be neuroprotective in Huntington’s disease, Parkinson’s 
disease and glaucoma through anti-oxidative and mitochondrial protective 
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mechanisms.52-55 Research from our laboratory has demonstrated the neuroprotective 
effect of short-term hyperglycaemia and intraocular glucose delivery in animal models 
of ischaemic retinal injury56,57 and experimental glaucoma58. In the clinical setting, 
topical59 and subconjunctival60 glucose delivery resulted in temporary recovery of 
contrast sensitivity in patients with severe primary open angle glaucoma. More recently, 
N-acetyl-cysteine amide has been observed to have a protective effect in animal models 
of traumatic brain injury by maintaining mitochondrial function.61,62 
Despite these promising results, the success of these bioenergetic agents in the clinical 
setting has been mostly limited and inconclusive.63-65  
 
1.4 Retinitis Pigmentosa  
Retinitis Pigmentosa (RP) is a group of hereditary retinal diseases that is characterized 
by the initial degeneration of rods followed by the subsequent loss of cones. It is one of 
the leading causes of inherited blindness, affecting 1 in 4000 with an estimated 1.5 
million individuals affected globally.66,67 The main mutations that result in RP involve 
the dysfunction of rod-specific proteins including rhodopsin in the phototransduction 
cascade. There are at least 50 genes currently known to cause non-syndromic RP with 
nearly 3100 mutations being reported in these genes. Syndromic forms of RP including 
Usher syndrome and Bardet-Biedl syndrome account for over 1200 pathogenic 
mutations.68 RP can be inherited in an autosomal-recessive (50-60%), autosomal 
dominant (30-40%) or X-linked pattern (5-15%) with non-mendelian digenic or 




1.4.1 Clinical presentation of RP 
The onset of symptoms is variable with some patients being asymptomatic until mid-
adulthood whilst others display symptoms in early childhood. Typically, the earliest 
manifestation is night blindness and difficulty with dark adaptation during adolescence. 
Patients may fail to recognize night blindness as most night activities are adequately lit 
to allow for compensation by cone-mediated vision. Patients may often present with 
vision loss after involvement of cone degeneration. Symptoms progress to involve loss 
of mid-peripheral vision which extends to far peripheral vision, creating a tunnel visual 
defect. Eventually, the central visual field becomes affected. Visual acuity can remain 
relatively normal in advanced RP with a remnant island of central vision. Up to 90% 
cone loss at the fovea may occur before there is a visual acuity reduction.70 On fundus 
examination, there are classically intra-retinal “bony spicule” pigmentary changes, 
severe arteriolar narrowing and a “waxy pallor” appearance of the optic disk. Electro-
retinograms (ERG) which record electrical response of the retina to light stimulus, 
initially demonstrate reduced scotopic and combined amplitudes before affecting 
photopic responses, signifying cone loss.71 Eventually, in late stage RP, the ERG 
response may be eliminated. Automated visual field testing reveals mid-peripheral 




Rod degeneration   
Due to the heterogeneity of RP, the precise mechanism of rod degeneration is unclear 
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and may vary depending on the affected gene. Generally, genetic mutations in RP lead 
to dysfunctional rod proteins or altered phototransduction pathways which trigger rod 
degeneration. Mutations in genes encoding for rhodopsin results in autosomal dominant 
RP and is the basis for the transgenic rodent model P23H rat.72 In these rats, rhodopsin 
accumulates high molecular weight oligomeric species within the cytoplasm 
predisposing to subsequent destruction by the ubiquitin-dependent proteasome system.73 
Genes affecting the rod OS structural proteins, rod outer segment 1 and peripherin 2, 
cause a variant of autosomal dominant RP.74  Rod degeneration in one form of 
autosomal recessive RP results from altered PDE6b activity, which leads to elevated 
levels of cGMP.75 Retinal degeneration mouse models of RP which feature this mutation, 
display high cGMP levels that precede photoreceptor and inner retinal degeneration.76 
Similarly, several in vitro studies have linked elevated cGMP to photoreceptor 
degeneration.76-78 The use of PDE6 inhibitors or cGMP analogues in human retinal 
explants lead to rod inner segment and cone structural changes with the combination 
virtually destroying all rods.79 Iodoacetate, a potent inhibitor of PDE6 results in raised 
cGMP and subsequent photoreceptor degeneration.80  
 
Cone degeneration  
Cones degenerate secondary to rod loss in RP. Analysis of RP patients with 18 different 
rhodopsin mutations revealed cone OS function remained normal until rod OS loss 
exceeded 75%, with the topography of cone loss strongly correlated to rod loss.81 The 
earliest event of cone degeneration is the deformation and loss of the cone OS.82 The 
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mechanism of secondary cone degeneration in RP is still unresolved yet there are 
several theories to explain the phenomenon.  
One explanation is the gap-junction mediated “bystander effect” which postulates that 
rod-derived products such as glutamate and apoptosis-promoting factors are released 
following rod cell death and propagate to cones via gap junctions, causing the death of 
these cells too.83 The “bystander effect” has been observed in cultures84-86 as well as in 
rodent models of transient cerebral ischaemia87.  In a study examining the effects of a 
transgene encoding normal rds/peripherin integrated into the X-chromosome in male 
and female rds-/- mutant retinas, Kedzierski et al.88 showed significant photoreceptor 
loss in both transgene-expressing and non-expressing retinal patches. The authors 
suggested that rod-derived toxin release from neighbouring cells was the cause of 
transgene-expressing photoreceptor death. More recently, this theory has been disputed 
by Kranz et al.82 who showed that mice deficient for the rod-cone coupling protein 
connexin36 did not show any delay or prevention of cone loss. Rod-derived toxin 
release would also be expected to affect nearby cells such as bipolar cells, however, 
these cells do not undergo widespread death following photoreceptor loss.89  
Another theory for secondary cone degeneration in RP is the role of microglial 
activation. The initiating event of rod death triggers the activation of microglial cells 
which migrate to the outer retinal and sub-retinal layers.90,91 Microglial cells release pro-
inflammatory cytokines, nitric oxide, tumour necrosis factor α, reactive oxygen species, 
excitatory amino acids, proteases and arachidonic acid derivatives which trigger cone 
death.92,93 Elevation of activated microglial cells have been identified in RP patients.92 
Upregulation of Toll-like receptor 4 as well as monocyte chemoattractant protein-1 and 
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CC Chemokine receptor 2 interaction has been linked to microglial activation in retinal 
degeneration mice models.94,95 Conversely, microglial activation may be modulated by 
the interaction between CXC3C chemokine receptor on microglial cells and its ligand 
CX3CL1 expressed by neurons either as a membrane bound or secreted ligand.96,97  In 
culture, retina-derived glial cells appear to release heat-inactivated, soluble molecules 
that induce apoptosis of photoreceptor cells.98 An essential flaw with the “bystander 
effect” and microglial activation theories is that neither can suitably explain the ongoing 
cone degeneration which occurs long after the destruction of all rods nor the fact that 
other cell types remain unaffected.  
Oxidative stress is an alternative mechanism to explain cone death in RP. Oxidative 
stress occurs when there is an imbalance between the generation of reactive oxygen 
species (ROS) and the cell’s antioxidant defence system. ROS production comes from 
various physiological biochemical processes including mitochondrial respiration, 
photochemical and enzymatic reactions, or from exposure to UV light, ionizing 
radiation, or heavy metal ions.99 Under physiological conditions within the retina, ROS 
derive via the high consumption of oxygen and are therefore produced mainly in 
mitochondria. Low levels of ROS provide physiological benefit by facilitating redox 
signaling pathways, cellular proliferation and gene expression. However, ROS are 
generally highly unstable and can interact with lipid, proteins and DNA to cause cell 
dysfunction and death, especially when present at elevated levels.  
One of the precipitating factors for oxidative stress is the elevated level of oxygen in the 
outer retina following rod loss.100 Rods, which constitute 95% of the photoreceptor 
population, consume most of the oxygen in the retina. Without rods, cones exposed to 
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hyperoxia undergo progressive oxidative damage and die. Cones in the mid-peripheral 
retina are lowest in density and are therefore highly predisposed to hyperoxia and 
subsequent oxidative damage resulting in the archetypal scotopic visual field defect 
described previously.101 Degeneration begins to affect other less dense regions, 
gradually progressing to higher cone densities, correlating closely to the pattern of 
visual loss in RP. Eventually, cones at the fovea are eliminated, causing complete 
blindness. Animal models of RP display biomarkers of oxidative damage such as 
acrolein and 4-hydroxynonenal-adducts.102,103  
Oxidative stress in RP has been linked to excess superoxide generation from activated 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in cones.104 Superoxide 
may lead to further ROS production or can directly affect surrounding cell structures. 
Cones contain abundant mitochondria, making them particularly susceptible to oxidative 
stress. Mitochondrial damage may lead to further ROS production, ultimately 
overwhelming the cone’s intrinsic antioxidant system. 
While excess ROS production has been linked to oxidative stress in RP, lower 
antioxidant levels have also been implicated. A study of RP patients revealed lower 
activity of the extracellular antioxidant enzyme, superoxide dismutase (SOD), in their 
aqueous humour as well as upregulated lipid peroxidation products in their blood.105 
Moreover, RP patients have been identified to have lower intraocular levels of the 
reduced antioxidant form of glutathione yet elevated levels of its oxidized form.106  
An additional argument for oxidative stress as a cause of cone degeneration is that 
antioxidant supplementation appears to preserve cone survival and ERG function in 
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mouse models of RP.103,107 . There is also evidence that oral antioxidant N-
acetylcysteine and its precursor N-acetylcysteine provide significant cone 
protection.101,108,109 Similarly, upregulation of SOD gene expression leads to substantial 
cone protection and preserved visual function in mice with RP.110,111  
Another explanation as to why secondary cone loss occurs in RP is that rods secrete 
trophic factors essential to cone survival. In rod-deficient retinas co-cultured with rod-
rich retinal tissue, cone loss was significantly attenuated, suggesting the presence of 
diffusible trophic factors.112 One such factor isolated from cone-rich chicken embryos 
has been identified as rod-derived cone viability factor (RdCVF).113 Two isoforms of 
this factor have been identified: the short isoform of RdCVF expresses cone protective 
activity whilst the long isoform RdCVF-L does not. Retinal explants transfected with 
RdCVF expressed a higher number of cones than control retinas.113 When RdCVF was 
removed from the medium through immunodepletion, cone protection became 
noticeably absent. In RP mouse models, RdCVF expression decreases during rod 
degeneration marking the onset of cone loss. Injection of exogenous RdCVF in 
autosomal dominant RP rats resulted in notable preservation of cones and their function 
as demonstrated by ERG.114  Similarly, upregulation of RdCVF gene expression in 
mouse models of rod-cone dystrophy improved ERG cone function and delayed cone 
loss.115 RdCVF may also play a role in combating retinal oxidative stress.116 A second 
trophic factor, RdCVF 2 and, more specifically, its short isoform variant, has been 
identified to have potential cone protection ability however its efficacy remains 




1.4.3 A potential bioenergetic mechanism of cone degeneration in RP 
More recently, evidence has emerged of a bioenergetic component in the mechanism of 
cone death in RP. The discovery of an RdCVF receptor, Basigin-1 (BSG-1), expressed 
in cone inner segments has provided a potential mechanism for RdCVF to stimulate 
cone survival through aerobic glycolysis.35 Aı¨t-Ali et al. revealed that BSG-1 itself 
binds to glucose transporter 1 (GLUT1) and this interaction increases glucose uptake to 
cones in the presence of RdCVF. The intracellular ATP concentration was also 
markedly elevated in RdCVF-treated cone cultures supplemented with glucose 
compared to negative control. Hence, rod loss would precipitate in RdCVF shortage and 
aerobic glycolysis compromise in cones. Subsequent energy failure would inevitably 
lead to cone death. The activation of the mammalian target of rapamycin (mTOR) 
signalling pathway has been attributed to cone preservation in RP.34,119 The mTOR 
signaling pathway is responsible for the regulation of cell growth, metabolism, 
proliferation and energy status.120 The mTOR protein is a serine-threonine kinase that is 
divided into two complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2). Activation of mTORC1 in retinal degeneration mouse models led to 
enhanced glucose utilization and retention in addition to maintenance of NADPH levels, 
which further  prevented caspase activation and apoptosis.119 As a result, cone survival 
was significantly prolonged suggesting that a metabolic disturbance may play a role in 
secondary cone loss. With energy deficiency as a possible component of cone 
degeneration in RP, a bioenergetic based intervention could therefore conceivably be 




Therapies for RP 
Currently, RP is an incurable condition. Vitamin A is the only treatment with 
demonstrable benefit in preserving electroretinographic cone function in RP patients.121 
Research on potential therapeutic modalities for RP currently include gene therapy122,123, 
photoreceptor transplantations124,125 and interventions targeting  biochemical 
pathways126.   
 
1.4.4 An overview of relevant animal models to study RP 
The use of animal models provides an essential foundation to study RP disease 
mechanisms and potential therapies. Rodent models are commonly used because of their 
cost-effectiveness and the availability of techniques for genetic manipulation 
(particularly in the case of mice). The Royal College Surgeons (RCS) rat displays retinal 
degeneration similar to RP caused by a genetic defect in the proto-oncogene tyrosine-
protein kinase MER protein (MerTK) resulting in accumulation of debris in the outer 
retina from impaired RPE phagocytosis of rod OS. RCS rats display degeneration 
beginning at postnatal day (P)15-20 and becoming complete by around P60. On the 
other hand, the P23H rat is a commonly used animal model for autosomal dominant RP. 
The primary genetic defect in this model is the substitution of histidine for proline at 
codon 23 in the rhodopsin gene. The resulting abnormal rhodopsin impairs rod 
function and subsequently triggers rod degeneration as early as P10, rapidly followed 
by secondary cone loss 127. By P180, most rods are depleted except for those in the 
periphery. Rod and cone degeneration occurs in a ring-like fashion, with degenerated 
retinal areas increasing in size and number between P90 and P180.128 
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The retinal degeneration-slow (rds) mouse is another model of RP that displays early 
onset retinal degeneration by P7 that slowly progresses. The ONL starts to degenerate 
by P14 and is completely obliterated within 12 months, with ERG readings becoming 
absent at this time.129 The genetic defect in the rds mouse is the insertion of foreign 
DNA into an exon of peripherin 2, resulting in the failure to develop rod OS.  
The retinal degeneration 10 (rd10) mouse is a model of autosomal recessive RP. 
Sequence analysis reveals a missense mutation in exon 13 of PDE6B. At 4 weeks, rd10 
mice display retinal degeneration with sclerotic vessels. The ERG declines as early as 
P18 before becoming non-existent at P60.129,130   
Arguably, the most well-known rodent model of autosomal recessive RP is the retinal 
degeneration 1 (rd1) mouse. The genetic defect in the rd1 mouse was established by 
murine viral insert and a second nonsense mutation in Exon 7 of the gene encoding for 
PDE6b. This defect results in cGMP accumulation which triggers photoreceptor 
degeneration.131 Rd1 mice are characterized by early onset severe retinal degeneration 
with rod loss beginning at P8-10 and completing by P21.76,132 By P21-28, the ONL 
progressively thins until there is only a single layer of cones that degenerate more 
gradually. The ERG signal is maximal at P14-15 and is comparable to age-matched 
normal mice but quickly declines, becoming undetectable at P21. Total loss of image-
forming vision occurs by P40 and degeneration of most cones occurs by P100. 76   
 
1.5 Photobiomodulation 
Photobiomodulation (PBM) or Red-Near Infrared (R-NIR) light therapy refers to the 
non-invasive irradiation of tissue with light in the far-red to near-infrared light spectrum 
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(630-1000 nm) with delivery methods varying from laser sources to light emitting diode 
(LED) devices.133 The study of the therapeutic properties of light in the far red and near 
infrared range of the spectrum (630 – 1000 nm) began in the 1960s when it was 
serendipitously observed that the recently invented ruby laser enhanced wound healing 
in rats. Over the ensuing decades the field of PBM has broadened to include treatment of 
a range of conditions. Despite a level of underlying skepticism of PBM due to the broad 
range of its purported applications, an increasing number of reports from well-respected 
groups mean that support for this treatment is increasing. Pertinently, more recently, 
focus has turned to the potential beneficial effects of PBM as a treatment for blinding 
retinal diseases. Positive effects for PBM have been demonstrated in various retinal 
disease animal models including those for light-induced retinal degeneration134-136, age-
related macular degeneration (AMD)137, retinitis pigmentosa138, diabetic retinopathy139 
and retinopathy of prematurity140,141 as evidenced by improved ERG , decreased 
inflammatory markers and  diminished cell loss.  
In terms of the clinic, there are some reports that state that PBM has yielded positive 
results in patients with AMD142,143, diabetic retinopathy144, amblyopia145 and Retinitis 
Pigmentosa146,  as reflected in improvements in visual acuity and decreases in visual 
field loss. However, these clinical studies range from interventional case series to a 
single case report and therefore evidence surrounding the clinical efficacy of PBM 
remains unclear. Thus, it is still a matter of debate as to whether PBM really has any 
positive effects against retinal diseases. Nevertheless the mechanism of PBM and its 




1.5.1 Mechanisms of Photobiomodulation 
Photobiomodulation targets Cytochrome C oxidase and unbinds nitric oxide 
The mitochondrially-bound electron transport complex component, cytochrome C 
oxidase (COX), represents the primary photo-acceptor in biological systems for 
red/infrared light. As a source of red/near infrared light, therefore, PBM necessarily 
targets COX, and thus, must affect electron transfer in the reduction of oxygen during 
mitochondrial respiration. This would increase both the mitochondrial membrane 
potential (MMP) and the synthesis of ATP (Figure 1.4). Ultimately, this triggers and 
enhances cellular repair processes and metabolism in photoreceptors, choroid cells and 
the retinal pigment epithelium.142 Evidence of COX as the primary target for PBM was 
confirmed by Eells who reported this treatment improved rat retinal function following 
methanol intoxication which is known to inhibit cytochrome oxidase activity.147 PBM 
treatment of primary cultured neurones has also been shown to reverse the effect of 
tetrodotoxin by upregulating COX activity.148   
Desmettre et al.149 found that PBM laser therapy to the choroid induced increased 
expression of heat shock proteins, which are known to stimulate cellular metabolism and 
prevent premature cell death.  
Another potential mechanism of PBM is the photo-dissociation of nitric oxide (NO) 
from COX as demonstrated by Karu et al.150. NO is non-convalently bound to COX via 
its heme iron and copper binding centres, competing with oxygen and thereby 
preventing mitochondrial respiration. Hence, NO dissociation from COX would restore 
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mitochondrial oxygen consumption, therefore increasing energy production and 
boosting cellular metabolic processes.133  
Activation of downstream retro-signalling pathways 
In vitro experiments have reported that PBM therapy increases phagocytosis and 
lysosomal activity, both of which assist in reducing  inflammation and enhancing repair 
of the retina.151 These processes result from PBM triggering downstream signaling 
cascades via changing cellular levels of ATP, cAMP, NO, ROS and Ca2+  and eventual 
altered gene expression, promoting anti-inflammatory processes, enhancement of anti-
oxidants defences and down-regulation of apoptosis as well as cell migration and 
proliferation.152 
Protein synthesis 
PBM has been demonstrated to increase protein expression in maturing epithelial cells 
in addition to collagen I production in human gingivial fibroblasts.153,154 Irradiation with 
660nm light also led to increased expression of collagen IV in skeletal muscles of 
injured rats. Similarly, osteoblasts showed elevated production of bone matrix proteins 
osteoglycin and mimecan following PBM.155   
Anti-inflammation 
PBM has been observed to decrease inflammation by inhibiting expression of 
prostaglandin E2, cyclooxygenase 1 and 2 mRNA expression in human fibroblast 
cells.156 The proposed mechanism was through modulation of the pro-inflammatory 
nuclear factor-kappa B signaling pathway. Moreover, PBM has been reported to 
decrease the pro-inflammatory mediators TNF-α, IL-1β, IL-6, IL-8, IL-10 and inducible 
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Nitric Oxide (iNOS) in animal models of arthritis, wound healing, inflammatory lung 
disease and auto-immune encephalomyelitis. 156-162 Downregulation of the complement 
system by PBM has also been reported in retinal degenerative diseases.163,164 
Modulation of oxidative stress 
It is possible that the action of PBM on COX, and therefore the electron transport chain, 
influences mitochondrial ROS production in healthy cells. However, PBM is known to 
decrease ROS production and therefore provide an anti-oxidative effect during oxidative 
stress.165 In culture, PBM has been observed to protect rat neural cells against oxidative 
injury and enhance neurite outgrowth.166 Decreased signatures of oxidative stress 
including protein carbonyls and thiobarbituric acid reactive species as well as increased 
expression of the anti-oxidant enzymes SOD, glutathione perioxidase and catalase were 
reported following PBM, in diverse animal models including skeletal muscle injury, 
diabetes-impaired wound healing and inflammatory pain.167-169 
Anti-apoptosis 
Prevention of apoptosis is another notable reported effect of PBM. For example, PBM 
partially prevented caspase-mediated apoptosis of cultured cortical neurons exposed to 
potassium cyanide.170 Furthermore, in an animal model of experimental autoimmune 
encephalitis, PBM stimulated the up-regulation of the apoptosis-preventative bcl-2 gene, 
which resulted in decreased neuron death within the spinal cord.162. A similar effect was 
observed in skeletal muscles of aged rats after PBM irradiation.171 Moreover, PBM 
treatment following experimental traumatic brain injury resulted in significant 




Cell migration and proliferation 
PBM is also known to promote wound healing by stimulating cell proliferation and 
migration. For example, red light irradiation enhanced proliferation and maturation of 
keratinocytes and this was associated with enhanced expression of the cell division 
driver, Cyclin D1.153 Likewise, human fibroblasts subjected to hyperglycaemia to 
simulate diabetes, and then exposed to PBM had an increased rate healing via 
proliferation and differentiation. This was associated with expression of epidermal 
growth factor and the “Janus kinase/Signal transducer and activators of transcription” 
(JAK/STAT) signalling pathway.173 Furthermore, of some interest, PBM stimulated 
proliferation, migration, differentiation and viability elevation in stem cells.174-176 This 
implies that since stem cell therapy is limited by the slow proliferation rate of 





Figure 1.4:  Schematic diagram of the proposed mechanisms of PBM. Near infrared 
light within wavelengths 630-1000 nm targets the mitochondrial enzyme Cytochrome 
C Oxidase resulting in 1) direct stimulation of mitochondrial respiration and 2) 
dissociation of nitric oxide which indirectly increases mitochondrial respiration. 
These processes result in elevation of ATP, cAMP, reactive oxygen species and 
intracellular calcium which impact downstream signalling pathways to increase anti-
inflammatory processes, protein synthesis, anti-apoptotic protein production, cellular 
repair/metabolism/proliferation/migration and cellular anti-oxidant defences. 
 
1.5.2 Treatment Parameters 
The dosage values of PBM treatments vary widely between studies. Lack of consistency 
is compounded by the fact that dose values can be expressed in terms of either 
irradiance levels or fluence. Irradiance or power density corresponds to the power 
received by a surface per unit area and is expressed as mW/cm2. Fluence, also known as 
energy density, refers to the energy received by a surface per unit area and is thus 
conveyed as J/cm2. Care must be taken when comparing different studies to interconvert 
data from fluence to irradiance, as appropriate (see Figure 1.5). The fluence range 
typically used is 1-20 J/cm2 while irradiance can vary greatly depending on the light 
source, spot size and purpose of therapy. Irradiances of 5-50 mW/cm2 are typically used 
for stimulation and healing with much higher irradiances used for analgesia and nerve 
inhibition.177 The frequency of treatment sessions can also vary with only a single 
session being needed for pain relief while chronic degenerative conditions can require 
ongoing frequent and multiple sessions.177-179 
The wavelength typically used in PBM is 670 nm although there have been a few 
studies that have compared the efficacy of different wavelengths. Wong-Riley et al.148 
reported the most effective wavelengths for preventing neuronal death from COX 
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inhibition were 670 nm and 830 nm, corresponding with maximal absorption spectra of 
COX. Giacci et al.180 noted 670 nm was more effective than 830 nm light in preserving 
visual function in a rat model of optic nerve transection.  Interestingly, Giacci et al.180 
also reported 670 nm but not 830nm light significantly reduced photoreceptor apoptosis 
in light-induced retinal degeneration despite the greater measured tissue penetrance of 
the latter wavelength. In the same study, neither 670nm nor 830nm light were effective 
in treating spinal cord injuries or traumatic brain injuries of rats. The authors concluded 
that the efficacy of the wavelength varied depending on the nature of the tissue and 
severity of injury.  
 




1.5.3 Laser VS LED PBM 
Previous studies have examined PBM delivered through either laser or LED.181 Laser is 
an acronym for “light amplification by stimulated emission of radiation”. Lasers use 
stimulated emission of electromagnetic radiation to produce a monochromatic coherent 
beam of light. On the other hand, LEDs are light sources that rely on the passage of 
electrical currents through semiconductor materials to release photons and subsequent 
light. Laser delivered PBM was long considered to be superior to LED-induced PBM 
due to their theoretically potential higher power densities and penetrance. However 
more recently, LED-delivered PBM has been increasingly preferred due to its safety, 
ease of use, ability to irradiate large areas and cost-effectiveness. Some comparative 
studies have suggested no difference in effectiveness between laser- and LED-delivered 
PBM however the majority of these studies have only examined wound healing.181-184 In 
consideration of tissues such as the retina which are of limited size and exist within an 
enclosed structure, laser PBM may be more beneficial due to less scattering. However, 
the comparative effectiveness between laser and LED PBM remains a controversial 
topic in PBM research. 
 
1.5.4 Biphasic dose response 
PBM has been observed to have a biphasic dose response whereby the magnitude of its 
positive effects increases in relation to the applied energy level until a particular dose is 
reached, after which effects are significantly less beneficial or even adverse. The 
biphasic dose response curve is consistent with “Arndt-Schulz law” which states that 
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weak stimuli slightly accelerates vital activity with stronger stimuli raising it further 
until a maximum response is reached. At this point, a stronger stimulus will cause 
suppression until a negative response is achieved. This phenomenon has been 
demonstrated on cortical neurons in vitro177,185 where it was noted that at low energy 
levels, PBM increased mitochondrial membrane potential, but that at high energy there 
was an adverse effect on this parameter, causing it to decline to below that of untreated 
cells. In rat models of myocardial infarction, beneficial effects were observed at 5 
mW/cm2 whilst higher irradiances of 25 mW/cm2 were associated with considerably less 
benefits.186 In another study, only treatment with an irradiance of 8 mW/cm2 out of a 
range of 0.7-40 mW/cm2 improved wound ulcers in irradiated mice.187 Chu-Tan et al.188 
further reported a biphasic dose response for PBM following low, medium or high light-
induced retinal injury in rats. In low or medium light-induced retinal injury, lower 
fluences of 9 J/cm2 and 18 J/cm2 decreased photoreceptor apoptosis, however 36 J/cm2 
was ineffective and 90 J/cm2 even increased photoreceptor death. With high intensity 
light-induced retinal injuries, only 90 J/cm2 PBM significantly reduced photoreceptor 
apoptosis, suggesting the efficacy of PBM dosages are intrinsically linked to the severity 
of damage. 
 
1.5.5 Photobiomodulation in degenerative retinal diseases 
1.5.5.1 Laboratory studies of PBM 
There have been numerous laboratory studies investigating the effect of PBM in rodent 
models of retinal degeneration.  
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1.5.5.1a Age-related retinal degeneration 
In an aged mouse model of retinal degeneration, Kokkinopoulos164 reported that PBM 
improved mitochondrial function in RPE cells and also reduced tissue inflammation. 
Following five treatments of NIR light exposure at 40 mW/cm2 lasting 90 seconds, 
researchers detected a significantly increased mitochondrial membrane potential as well 
as reducing Complement Component C3d, pro-inflammatory cytokine TNF-α and total 
macrophage numbers. This was confirmed by Begum et al..137 who reported similar 
results in Complement Factor H (CFH) knockout mice. Mice exposed to R/NIR light at 
20 mW/cm2 for 6 minutes twice daily for 2 weeks had significantly increased COX 
expression, decreased Complement C3 deposition in the outer retina as well as reduced 
reactive gliosis markers vimentin and GFAP. There were also notable changes in the 
morphology of RPE cells, macrophages and dendritic cells however there was no 
significant change in numbers. It is important to note here that the relatively indirect 
delivery of PBM through supplemental environmental lighting in this study 
demonstrated the effectiveness of RR/NIR light in penetrating tissue to reach the target. 
Calaza et al.189 reported improved retinal ATP levels in CFH knockout mice following 
R-NIR light exposure at 40 mW/cm2 supporting evidence that PBM improves oxidative 
phosphorylation. In a separate experiment, Kokkinopoulos190 reported that PBM can 
drastically ameliorate inflammation from innate immunity. CFH knockout mice 
exhibited decreased Complement C3b expression in the outer retina following exposure 
to regular 90 second doses of R/NIR light twice a day for two days at 40 mW/cm2 over 8 
weeks. Interestingly, Toll-like receptor 2 (TLR 2) 2 and Toll-like receptor 4 (TLR 4) 
expression decreased in the retinal inner nuclear layer but not in the RPE in these 
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animals showing differential effects on distinct cell types. Expression of the systemic 
inflammatory marker calcitonin was also significantly decreased in all layers.  
1.5.5.1.b Retinal light toxicity 
In a light induced model of atrophic AMD, 3 minutes of daily R/NIR light exposure at 9 
J/cm2over 5 days was reported to reduce complement propagation, C3 deposition, 
photoreceptor death and oxidative stress.163 Abarracin et al.191 also reported a significant 
decrease in photoreceptor apoptosis, mitigation of OS loss, preservation of the opn1mw 
cone opsin gene and improvement of cone ERG b-wave amplitudes in eyes treated with 
3 minutes of  PBM at 60 mW/cm2 irradiance compared to untreated eyes in a light-
induced AMD rodent model.  In this light-induced AMD model, Natoli et al.192 were 
able to show down-regulation of genes for the proinflammatory cytokine ccl2, and stress 
factors GFAP and  fgf-2 in PBM treated eyes, further suggesting that PBM interacts 
with inflammatory and apoptotic pathways. In a retinopathy of prematurity rodent 
model, Natoli et al. 140 reported decreased vaso-obliteration, neovascularization and 
peripheral retinal vessel branching after PBM. Similarly, Di Marco et al.193 described 
PBM preconditioning 2-10 days prior to light-induced retinal injury with reduced 
photoreceptor apoptosis, ameliorated ONL thinning and downregulated GFAP 
expression in Müller cells. In a non-human primate model of laser-induced retinal 
injury, Eells et al.194 reported preservation of multifocal ERG amplitude and total retinal 
thickness following PBM treatment. Most remarkably, as the authors reported 
upregulation of COX expression in the lateral geniculate nucleus suggesting extension 
of PBM benefits beyond the treated retina.  
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1.5.5.1c Retinitis Pigmentosa 
In P23H rats, Eells et al.195 described decreased photoreceptor apoptosis and 
upregulation of COX, ciliary neurotrophic factor (CNTF) and mitochondrial superoxide 
dismutase (Mn-SOD) in PBM treated eyes.  
1.5.5.1d Other retinal degenerative models 
PBM has also been demonstrated to decrease oxidative stress and inflammatory markers, 
protect retinal ganglion cells as well as improve visual function in diabetic retinopathy 
139,196 in addition to optic nerve injury197,198 rodent and in-vitro models.  
 
1.5.5.2 PBM clinical studies 
There have been clinical studies that suggest PBM provides benefit for sufferers of 
degenerative retinal disease, however, they are largely limited and far from robust in 
design.  
1.5.5.2a Retinitis Pigmentosa 
A single case report of PBM on an RP patient noted improvements in both visual acuity 
and visual field following four treatments provided over two weeks.146The study 
involved irradiation of the whole retina with 780 nm light from a continuous wave laser 
diode, lasting 40s at a total of 0.4 J/cm2 per treatment. Interestingly, the patient’s visual 
acuity was maintained for a further five years before a visual decline to pre-treatment 
levels. Reportedly only another four treatments were required to restore vision gains. 
The evidence of general benefit in this case remains at best unsubstantiated given the 
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small sample size, subjective nature of visual acuity measurements and the unexplained 
mechanism of maintaining vision over years despite only four treatments. 
1.5.5.2b Diabetic macular oedema 
Tang et al.144 reported significant reductions in non-central diabetic macular oedema and 
focal retinal thickness in four eyes of four patients following PBM. Eyes prior to 
treatment had perfect visual acuity which was generally preserved post-treatment. The 
efficacy of PBM is difficult to conclude in this case series given the non-randomized 
design, absence of placebo control, small sample size and no mechanistic explanation 
for the observed reduction of retinal oedema.  
1.5.5.2c Age-related Macular Degeneration 
There have also been several clinical studies investigating the effects of PBM on AMD 
patients including a prospective study by Ivandic and Ivandic142 where 348 eyes of 203 
patients with dry and wet type AMD were exposed to 40 seconds of  780 nm light from 
a semiconductor laser diode with 0.3 J/cm2 delivered to the macula  four times over 2 
weeks. The treatment group included 146 eyes with cataracts and 182 without. The 
remaining 20 eyes of 10 patients received sham treatments and served as the control 
group. There was substantial improvement in both treated groups with 97% of patients 
with cataracts improving in visual acuity by a mean of 2 lines and 94.5% of the non-
cataract patients by the same amount up to 36 months. The authors also reported 
reduced pigmentation and cystic drusen as well as improvement in metamorphopsia, 
dyschromatopsia and relative scotomas. Patients with wet AMD had reduced oedema 
and bleeding. No change was observed in the control group. The TORPA II study, 
which examined 42 eyes in 24 patients with dry AMD by Merry G et al..199 consisted of 
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delivering 88 seconds of 670 nm light at 4-7.7 J/cm2 through LED-based devices as well 
as 590 and 790 nm for 35 seconds delivering 0.1 J/cm2 in nine treatments over 3 weeks. 
Following PBM, there were positive functional changes indicated by improvement of 
contrast sensitivity and visual acuity at 3 weeks and 3 months as well as anatomical 
improvement exhibited by decrease in drusen volume and central drusen thickness. 
However, there were significant flaws in the methodologies of both studies: lack of a 
suitable control arm or significant number discrepancies between treatment groups, 
large ranges in total dosages delivered, as well as  a broad patient demographic with 
varying stages of disease being noted and uncontrolled. Hence, it is difficult to conclude 
clinical efficacy of PBM in these studies. 
 
1.5.6 Safety profile 
PBM has an impressive safety profile likely due to the low-power and non-thermal 
nature of the administering devices (lasers and LEDs). Furthermore, R/NIR laser 
treatment is non-invasive compared to surgery or intravitreal injections, which are used, 
for example, in the treatment of wet AMD. The treatment regimens in previous studies 
have used mainly LED to deliver R-NIR light and have varying dosages, duration and 
frequency. Therefore, there is currently no consensus on treatment parameters in 






1.6 Aims of the study 
1.6.1 Rationale for the study 
The overall rationale behind the study is the  exploration of novel strategies to protect or 
prevent degeneration of photoreceptors in devastating retinal diseases such as RP34,35, 
AMD36,37, diabetic retinopathy38 and central retinal artery/vein occlusion39,40. It is 
believed that one common component in the pathogenesis of these conditions is a degree 
of energy deficiency to part of the retina. Hence, it is hypothesized that one pertinent 
avenue of treatment would be based on the principle of augmenting the available retinal 
energy supply.  
As stated, PBM has been found in previous studies to increase cellular metabolism, 
energy availability and metabolic repair processes. PBM is thus believed to provide a 
strong protective effect to cells that have been exposed to injury, particularly when the 
insult is based upon an energy deficit. The overall focus of this work, therefore, was to 
investigate whether PBM represents a valid neuroprotective strategy in the treatment of 
blinding eye diseases, especially involving degeneration of photoreceptors, and 
especially where an energy deficit is likely involved.  
 
1.6.2 Specific aims of the study 
(1) To assess the safety profile of the R/NIR laser as our means of applying PBM to 
a rodent retina and to define suitable parameters for treatment with this laser.  
An important consideration in the development of a novel disease treatment is whether 
the intervention alone causes any detrimental effects. To this end, the first experiment 
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was designed to investigate the safety profile of PBM in rodent eyes. More specifically, 
R/NIR light was applied to rodent eyes, via laser treatment, to determine whether it 
caused any adverse or detrimental effects to the retina. 
(2) To determine whether PBM, as applied by R/NIR laser, could prevent 
secondary cone degeneration in the rd1 mouse model of inherited photoreceptor 
loss. 
Having established both a suitable safety profile and the operating parameters for the 
PBM treatment, our second experiment was to examine the neuroprotective efficacy of 
this treatment for the rd1 mouse model of autosomal recessive RP. We undertook this 
investigation by examining the effect of PBM in preserving cones and their function in 




2. Materials and Methods 
2.1 Animals ethics and handling 
Permission to use animals was obtained from the Central Adelaide Local Health 
Network Animal Ethics Committee. The work undertaken conforms with both the 
Australian Code of practice for the Care and Use of Animals for Scientific Purposes, 
2013, and to the ARVO statement for the Use of Animals in Ophthalmic and Vision 
Research. Animals were obtained from the University of Adelaide, Adelaide, South 
Australia. They were housed in temperature- and humidity-regulated rooms with 12 
hour light and 12 hour dark cycles. Food and water were provided ad libitum. Prior to 
procedures in the first experiment, animals underwent general anaesthesia with an 
intraperitoneal injection of a mixture of 100mg/kg ketamine (Sigma-Aldrich, Missouri, 
USA) and 10mg/kg xylazine (Sigma-Aldrich, Missouri, USA). In the second experiment, 
only isofluorane was required for anaesthesia throughout the laser procedure.  At the 
conclusion of the experiment, animals were humanely killed with transcardial perfusion 
of physiological saline under general anaesthesia. Globes with optic nerve attached were 
then carefully dissected. The superior aspect of the conjunctiva was marked with a dye 
for the purpose of orientation. 
 
2.2 Laser equipment 
The system comprised a slit-lamp (Ellex Medical Lasers, Adelaide, South Australia, 
Australia) that emits a 670 nm laser (Figure 2.1). The beam was 4.5 mm in diameter 
with a flat-top profile. Depending on the treatment group, the power setting was 
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adjusted according to a reference table created by Ellex Medical Lasers that took into 
consideration the animal’s maximum dilated pupil size to produce the intended 
irradiance at the retina. 
.  
Figure 2.1 Laser equipment set-up. The anaesthetised rat is placed onto a custom-
designed platform attached to a slit lamp. The irradiance dose was produced by 
adjusting the power setting with reference to a setting conversion table. 
 
2.3 Laser procedure 
Once the animal was anaesthetised, a drop of 1% tropicamide (Bausch and Lomb, New 
York, USA) and a drop of 0.4 % oxybuprocaine (Bausch and Lomb, New York, USA) 
were sequentially applied to one eye, in order to dilate the pupil and provide local 
anaesthesia, respectively. The animal was placed on a specially designed platform 
attached to the slit lamp. The fundus was then visualized by holding a microscope 
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coverslip lubricated with methylcellulose against the cornea of the eye. The power 
setting was adjusted to reflect the intended irradiance (Figure 2.2). Focusing and 
centring on the optic nerve head, continuous 670 nm laser was applied for 90 seconds 
(Figure 2.3). The fellow eye served as a control. Following the procedure, the animal 
was placed back into its cage that was heated to 37˚C to maintain body warmth. 
 
Figure 2.2: Power calibration table provided by Ellex lasers for the PBM laser. The 





Figure 2.3: Confocal scanning laser ophthalmoscopy fundus photo with depicted 
irradiation zone. During the laser procedure, the fundus was visualized with a 
microscope coverslip lubricated with methylcellulose applied to the cornea.  
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2.4 Scotopic Electroretinography (ERG)  
Animals were dark adapted overnight and prepared under dim red light in order to 
maintain adaptation.Animals were placed under intraperitoneal anaesthesia (ketamine 
100 mg/kg and xylazine 10 mg/kg). Single drops of both anaesthetic (oxybuprocaine) 
and pupil dilator (tropicamide) was applied to each eye. The animal was placed on a 
heated platform to maintain body temperature throughout the procedure. Gold electrodes 
were used with the positive electrode placed on the central cornea, the reference 
electrode on the tongue and the ground electrode was attached to the scruff of the neck 
(Figure 2.4). Preservative-free lubricating eye drops (0.4% polyethylene glycol 400, 0.3% 
propylene glycole) were applied intermittently to prevent exposure keratopathy. A 
single bright light flash from a mini-ganzfeld photic stimulator (brightness of 20 cd⋅s/m2, 
duration 10 ms, distance 10 cm) was directed at the animal’s eye. The signals were 
amplified (gain set at 1000) and filtered (0.3 Hz high pass-300 Hz low pass) with a DC 
amplifier (ADI instruments, New South Wales, Australia). All recordings were 
performed under complete darkness. Ten responses were recorded and averaged with 
LabChart software (ADI instruments, New South Wales, Australia). The a-wave 
amplitude was measured from the pre-stimulus amplitude to the trough of the a-wave. 
The b-wave amplitude was measured from the trough of the a-wave to the peak of the b-
wave (Figure 2.5). The negative a-wave reflects the reduction in the ‘dark’ currents from 
light absorption in the photoreceptor outer segments and closure of cGMP-gated 
cationic channels.200 Hence, the a-wave is representative of photoreceptor function. The 
b-wave represents inner retinal function. It derives from changes in the membrane 
potential of Müller cells in response to light-induced increases in extracellular potassium 
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from depolarized bipolar cells.201 The implicit time, which refers to the time from the 
start of stimulus to the peak of the wave, was also measured for the a- and b-wave.  
 
Figure 2.4 ERG set-up. The anaesthetized animal was placed onto a platform heated 
to 37˚ C. The positive electrode was placed lightly on the central cornea. The negative 
electrode and ground electrode were applied to the tongue and scruff of the neck, 
respectively.  Recordings were performed in the dark with the animal dark-adapted 




Figure 2.5 Representative ERG from a normal, untreated animal. Ten recordings 
were averaged and saved on Labchart. The a-wave amplitude, which represented 
photoreceptor function, was recorded as the pre-stimulus amplitude to the trough of 
the a-wave. The b-wave, which denotes inner retinal function, was measured from the 
trough of the a-wave to the peak of the b-wave. Implicit times for the a- and b-waves 
were measured from the start of the stimulus to the peak of the wave.  
 
2.5 Spectral Domain Optical Coherence Tomography (SD-OCT) 
Animals were anaesthetised with intraperitoneal ketamine/xylazine before receiving a 
drop of topical tropicamide to dilate the pupils, and then placed on a custom designed 
platform in a position so that the eye faced the camera. Capture of SD-OCT images was 
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performed using the Heidelberg Spectralis (Heidelberg Engineering, Heidelberg, 
Germany). A wide-field 55° lens was used to capture an overall view of the retina.  A 
series of 97 B-scan SD-OCT images were captured at the optic nerve head, entirely 
contained within the lasered area and measuring 2.4 mm x 1.7 mm. The distance 
between each B-scan was 18 µm. A confocal scanning laser ophthalmoscopy image of 
the corresponding fundus was also taken. The corneal-curvature was adjusted to 3.0 mm, 
appropriate for rats, to allow accurate scaling for subsequent thickness measurements.202 
Throughout the procedure, preservative-free lubricant eye drops (0.4% polyethylene 
glycol 400, 0.3% propylene glycole) were administered to the eye to prevent corneal 
dryness and image artifacts. The total retinal thickness and outer nuclear layer (ONL) 
thickness were measured at specified points using the in-built Heidelberg Spectralis 
software (Figure 2.6). Thickness measurements were averaged for each eye. 
 
 
Figure 2.6 Representative SD-OCT image. Three SD-OCT slices (A, B and C) at 480 
µm apart were used for each eye. The retinal cross-section of slice B is shown as an 
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example. Four measurements of total retinal thickness and ONL thickness were taken 
in each slice. Measurements were taken at a horizontal distance of 500 µm and 1000 
µm from the centre of the optic nerve on each side. This produced 12 measurements 
for total retinal thickness and ONL thickness. Measurements were then averaged for 
each eye.  
 
2.6 Fluorescein angiography (FA)  
The animal was anaesthetized with intraperitoneal ketamine/xylazine, as described 
above, before a drop of the pupil dilator, tropicamide, was applied. Fluorescein (10%, 
w/v) 5 mL was injected intraperitoneally. The animal was then placed on the custom 
designed platform facing the camera. FA images were taken with the Heidelberg 
Spectralis in Angiography mode (Figure 2.7). FA images of the retinal vessels focusing 
on the area of the optic nerve head were captured at 0, 5, 10, 15 and 20 minutes after 
fluorescein injection. Preservative-free lubricant eye drops (0.4% polyethylene glycol 
400, 0.3% propylene glycol) were administered to the eye to prevent corneal dryness 
and image artifacts throughout the scanning process. Images were analyzed for any 
leakage which was defined as any focal hyperfluorescence that increased in intensity 




Figure 2.7 Representative FA image captured by confocal scanning laser 
ophthalmoscopy with the Heidelberg Spectralis in angiography mode. 
 
2.7 Optokinetic Response 
The optokinetic test is commonly used to measure the visual function of an animal by 
observing the maximum spatial frequency of a rotating visual stimulus for which the 
animal responds with a head reflex.203 Animals were placed on a platform on a floor 
mirror surrounded by computer monitors that formed an enclosed area and allowed a 
continuous movement of the projected image. Vertical sine wave gratings (100% contrast) 
were projected on the computer monitors. The spatial frequencies tested were 0.05, 
0.075, 0.1, 0.2, 0.3, 0.4, 0.5, and 0.6 cycles per degree (cpd). A camera was placed above 
55 
 
the platform to observe and record the animal’s head movements. Mice were placed one 
at a time on the platform and allowed to acclimatize to their surroundings before starting 
the stimulus. The stimulus consisted of a grating perceptible to the mouse that was 
projected on the cylinder wall which rotated at a constant 12 degrees /second. Two 
independent experimenters blinded to the treatment groups monitored for a head reflex 
characterized by the animal displaying reflexive head movements corresponding to the 
direction and speed of the cylinder rotation that was not accompanied by any other body 
movements. A positive response was recorded only if the reflexive head movement 
occurred within the first 15 seconds of the stimulus and there was agreement between 
the experimenters. Assessment of the left or right eye was dependent on cylinder 
direction.204 Clockwise direction of the cylinder corresponded to the left eye whilst 
counterclockwise direction was related to the right eye. The spatial frequency of the grating 
was progressively increased until the animal no longer responded. The maximum spatial 
frequency for a positive head reflex was recorded. This was repeated for each eye. 
Recorded videos of the test were reassessed by an independent observer for each mouse 
to avoid discrepancies in recorded results. 
   
2.8 Retinal whole-mounts 
2.8.1 Dissection  
Eye globes were immersed in 10% (w/v) neutral buffered formalin for at least 24 hours 
before dissection. Dissection was performed under a high magnification operating 
microscope with the globe immersed in phosphate buffered saline (PBS) solution 
containing 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM KH2PO4. An initial 
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cut was made below the ora serrata with a scalpel blade. With straight-blade spring 
scissors, the cut was extended circumferentially until separation between the anterior 
and posterior segments was achieved. At the point of the marked conjunctiva on the 
posterior eye cup, a small radial cut was made to signify the superior retina. Larger 
radial cuts were made to create the four “petal” quadrants of the retina whilst still 
attached to the RPE. Straight fine forceps were used to grasp the one side of the RPE 
petal behind the retina whilst angled forceps were applied on the other side. By pulling 
the forceps in opposite directions, the RPE petal was gently peeled away from retina. 
This was repeated for all remaining quadrants. Finally, blunt dissection was used to 
separate the retina from the RPE at the optic nerve head. 
 
2.8.2 Immunohistochemistry 
Initially, retinas were incubated in PBS containing 1% (v/v) Triton X-100 detergent 
(PBS-T) for 1 hour at room temperature. Next, retinas were incubated in PBS-T 
containing 3% (v/v) normal horse serum (NHS-T) for 1 hour at room temperature to 
block non-specific antibody binding. Retinas were then incubated overnight at 4°C with 
a combination of primary antibodies diluted in NHS-T. Anti-S-opsin antibody (see 
Table 2.1) was used to detect short-wave sensitive cones, whilst anti-M/L opsin 
antibody (see Table 2.1) was used to detect medium/long wave sensitive opsin cones.  
On day 2, retinas were washed for 1 hour at room temperature in PBS-T, then incubated 
overnight at 4°C with a combination of AlexaFluor-488 and -594 conjugated secondary 
antibodies (1:250; Invitrogen, Carlsbad, CA) diluted in NHS-T. Finally, retinas were 
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washed in PBS for 1 hour at room temperature prior to mounting with the photoreceptor 
side facing up, using anti-fade mounting medium (Dako, California, USA). 
 
2.8.2 Quantification  
All analyses were conducted in a blinded fashion. Photomicrographs of wholemounts 
were taken with an epifluorescent microscope with attached fluorescent optics (BX-61; 
Olympus, Mount Waverly, VIC, Australia). Rectangular areas of 350 x 250 µm were 
photographed adjacent to the optic disk and 2 mm away from the optic disk in each of 
the retinal quadrants (Figure 2.8). This yielded 8 photos per retina. Quantification of 
cone survival was performed using Image-J software (NIH, Bethesda, Maryland, USA). 
Initially, however, images were processed in Photoshop CS3 (Adobe). Images were 
corrected for uneven lighting using a flatten filter and where necessary linear gradient 
tool, then sharpened, levels enhanced, and finally converted to 8-bit mode.  
 
Cone cell bodies were identified by both their wide ovoid morphology, segments by their 
narrow, bundle-like appearance. For determination of total S-cone and total M/L-cone 
labelling, images were manually thresholded until all cone cell bodies and segments 
were highlighted. The area in pixels was then calculated with the “analyze particles” 
function, using a minimum size of 5 square pixels. As shown in section 4.3.4 ML-opsin 
segments stained with greater fluorescent intensity then cell bodies. This permitted 
quantification of M/L-opsin-labelled cone segment survival (which necessarily 
comprises both genuine M/L-cones and dual cones). Quantification of segments was 
performed by adjusting the image threshold to isolate the more intensely stained M/L-
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opsin segments. The area in pixels was then calculated with the “analyse particles” 
function, using a minimum size of 5 square pixels. In contrast to M/L-opsin, S-opsin 
cone cell bodies and segments stained with similar intensity. Hence, quantification of S-
opsin cones included both cone cell bodies and segments.  
 
For characterisation of the proportion of genuine M/L-cones, genuine S-cones, and dual 
cones in 60 day old rd1 mice, images captured from the superior, inferior, temporal and 
nasal quadrants of the peripheral retina of 24 animals were analysed. In Photoshop CS3, 
each pair of S-Opsin and M/L-opsin images were corrected for uneven lighting using a 
flatten filter, and where necessary linear gradient tool, and adjusted to be of 
approximately the same intensity. The images were then merged (M/L-opsin, green 
channel; S-Opsin, red channel), sharpened, levels enhanced, filtered for “noise/dust” and 
finally converted to 8-bit mode. In Image-J software, colour thresholding was performed 
on each merged image to determine the proportion of “red”, “yellow” and “green” cones, 
which correspond to “genuine S-cones”, “dual cones”, and “genuine M/L-cones”, 
respectively. To facilitate this goal, the total area of “all” cones within the image was 
first determined by manually thresholding using the “brightness” scale, with “saturation” 
and “Hue” set at the maximum range of 0-255. Next, to delineate the proportion of 
individual cone types, the “Hue scale was altered as follows: Hue 0-14 (red), Hue 14-50 
(yellow), Hue 50-150 (green). For each “Hue” setting, the area in pixels was calculated 
using the “analyze particles” function, using a minimum size of 100 square pixels to 
remove background any debris or shards of staining. For each Hue setting, a mask of the 





Figure 2.8 Schematic diagram of wholemount retina with photographic areas selected 
for quantification. Photographic dimensions were 350 µm x 250 µm. The central 
photographs were taken immediately adjacent to the optic nerve head whilst the 
peripheral photographs were captured 2 mm from the optic nerve head. Central and 
peripheral photos were taken for each region: superior, inferior, nasal and temporal.  
 
2.9 Retinal transverse sections 
2.9.1 Tissue preparation 
Prior to enucleation, the superior aspect of each globe was marked using surgical ink. 
Eyes with globe attached were carefully removed and placed in 10% neutral buffered 
formalin for at least 24 hours. Tissues were processed by sequential immersion in 70% 
ethanol for 30 min, 3 × 100% ethanol for 30 min, 2 × xylene for 30 min, 50% xylene/50% 
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wax for 30 min at 62°C followed by 2 × wax for 30 min at 62°C. Eye globes were 
embedded sagittally in paraffin. Following the embedding process, 4 µm serial sections 
were cut with a microtome. Tissue sections were stained for hematoxylin and eosin 
using a standard methodology. 
 
2.9.1 Immunohistochemistry  
Tissue sections were deparaffinised, rinsed in 100% ethanol and treated for 20 min with 
hydrogen peroxide in absolute methanol to block endogenous peroxidase activity. 
Antigen retrieval was achieved by microwaving the sections in 1mM EDTA buffer (pH 
8.0) for 10 min at 95 – 100°C. The microwave used, NEC N702EP, had been previously 
calibrated such that a stable temperature range of 95 – 100°C was achieved when two 
preheated plastic containers, each filled with 250 ml of retrieval solution, were 
microwaved on power setting 2. Tissue sections were blocked with PBS containing 3% 
normal horse serum and incubated overnight at room temperature in primary antibody 
containing 3% normal horse serum (Table 2.1). Subsequent to this, consecutive 
incubations were carried out with biotinylated secondary antibody (1:250; Vector, 
Burlingame, CA) and streptavidin–peroxidase conjugate (1:1000; Pierce, Rockford, IL). 
Color development was achieved using 3,3’-diaminobenzidine. Sections were 
counterstained with hematoxylin, dehydrated, cleared in histolene, and mounted in DPX.  
 
2.9.2 Quantification  
All analyses were conducted in a blinded fashion. Photomicrographs of stained 
transverse tissue sections were taken under a light microscope (BX-51; Olympus, Mount 
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Waverly, VIC, Australia). From each stained section, rectangular areas of 350 x 260 µm 
were photographed adjacent to the optic nerve head on each side, and 1 mm away from 
the optic nerve head on each side. For quantification of GFAP, iba1, FGF-2 and CNTF, 
the immunoreactive area in each photomicrograph was demarcated. Firstly, colour 
deconvolution was applied to extract the DAB staining. Any uneven illuminated 
background was removed using the “rolling ball” method. After manual thresholding, 
the area of positive staining was then measured. Evaluations were performed using the 
ImageJ 1.42q software package platform (http://rsb.info.nih.gov/ij/). 
 
Table 2.1 Antibodies used in the study 
Target Host Clone/#Cat No. Dilution Source 
CNTF goat #AF 557-NA 1:1000 R&D Systems 
cone arrestin rabbit #AB15282 1:5000 Merck-Millipore 
FGF-2 mouse clone bFM-2 1:500 Merck-Millipore 
GFAP rabbit #Z0 334 1:40,000 Dako 
iba1 rabbit #019-19741 1:20,000 WAKO 
M/L-opsin rabbit #AB5405 1:1000 Merck-Millipore 
RPE65 goat sc-53489 1:3000 Santa-Cruz 




2.10 Statistical analysis 
Data are presented as mean ± SEM. In chapter 3, ERG and SD-OCT measurements at 
baseline and post-laser were analyzed with a paired t-test for each treatment group. 
Immunohistochemistry for GFAP, iba1, FGF-2 and CNT were analysed by ANOVA. In 
chapter 4, cone cell body, cone OS counts and optokinetic responses were analyzed 
between treatment groups with one-way ANOVA followed by post-hoc Tukey’s test or 
a paired t-test for matched values. Statistical analysis and generation of graphs were 
performed with GraphPad Prism software (GraphPad Software V6, La Jolla, CA). P 




3. A safety study of photobiomodulation laser on the rat retina 
3.1 Introduction 
Chapter 3 represents the findings of the photobiomodulation (PBM) safety study. To 
date, the benefit of PBM in degenerative retinal disease has essentially been studied 
through LED delivery of R/NIR light. There is currently no consensus on whether 
coherent laser-delivered irradiation is superior to non-coherent LED sources; studies on 
wound healing have found no difference in effect;205,206 however, coherent R/NIR light 
may be required for adequate exposure for the retina, which is housed within the 
enclosed structure of the eye. LED-delivered PBM leads to a theoretical random 
scattering of incoherent irradiation that may be variably filtered and absorbed by ocular 
structures. As a result, accurate treatment parameters for the retina are difficult to 
determine and present as a barrier to clinical translation. Herein, a custom-designed 
PBM laser attached to a slit lamp has been used to address this conundrum. Of 
importance, the safety threshold of laser-based PBM of the retina has not been 
investigated. Prior to assessing the neuroprotection efficacy of laser-delivered PBM, it is 
imperative to examine whether any adverse effects occur. Hence, the purpose of the 
experiments detailed in chapter 3 was to examine the safety of a range of irradiances of 




3.2 Study design 
3.2.1 Safety in pigmented – Dark Agouti (DA) – rats, analysed one week post-PBM 
Experiment 3.1 comprised 10 DA rats (n=20 eyes) that received PBM laser at the 
following irradiance doses: control (n=4), sham (aiming beam only, n=4), 25 mW/cm2 
(low dose, n=4), 100 mW/cm2 (medium dose, n=4), 500 mW/cm2 (high dose, n=4). 
Owing to one of the high dose eyes displaying localised peripapillary changes, ie. 
changes around the optic disk, the study was extended by a further 7 rats as follows: 
control (n=2), sham (n=3), 100 mW/cm2 (n=3) 500 mW/cm2 (n=6). In total, therefore, 
the number of eyes analysed in each group was as follows: control (n=6), sham (n=7), 
25 mW/cm2 (n=4), 100 mW/cm2 (n=7), 500 mW/cm2 (n=10). 
 
Rats received three PBM treatments aimed at the optic nerve (Figure 2.3) on non-
consecutive days and were killed one week after the final laser session (see Figure 3.1). 
SD-OCTs were performed on all rats at baseline and prior to humane killing to assess 
for structural and functional changes. Total retinal thickness and outer nuclear layer 
(ONL) thickness were measured at preselected points (as detailed in Chapter 2). 
Concurrent with SD-OCT scans, fundus images were captured using a confocal 
scanning laser ophthalmoscope. ERGs were conducted at baseline and at 7 days post-
laser. The amplitude and implicit times of the b- and a- wave were measured from the 
average of 10 ERG recordings for each eye. Whilst under terminal anaesthesia, each rat 
underwent a fluorescent angiogram (FA) for 20 minutes to assess vascular integrity. 
Rats were humanely killed by transcardial perfusion with physiological saline followed 
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by neutral buffered formalin, and the eyes were then dissected for histological analysis 
(see chapter 2).  







 Figure 3.1 Experimental plan and timeline of experiment 3.1 
 
3.2.2 Safety in pigmented – DA – rats, analysed three days post-PBM 
A follow-up safety study (experiment 3.2) was performed in which rats were analysed at 
an earlier time point, 3 days compared to 7 days, in order to establish whether any overt 
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vascular leakage or retinal edema was evident in the first few days following multiple 
sessions of PBM. The experimental design (see Figure 3.2) was as follows: sham (n=3), 
100 mW/cm2 (n=3), 500 mW/cm2 (n=6). SD-OCT and fundus images were taken pre- 
and post-PBM. FA was also performed. Eyes were then analyzed for histology. 










3.2.3 Safety in albino – Sprague Dawley (SD) – rats, analysed one week post-PBM 
A final safety study (experiment 3.3) was performed using a non-pigmented rat strain in 
order to reveal whether the peripapillary damage that was sometimes manifest at the 
high dose of PBM in DA rats was related to absorption by the heavily pigmented 
RPE/choroid. The experimental design (see Figure 3.3) was as follows: sham (n=3), 100 
mW/cm2 (n=3), 500 mW/cm2 (n=6). SD-OCT and fundus images were taken pre- and 
post-PBM. FA was also performed. Eyes were then analyzed for histology. 
68 
 










3.3.1  Experiment 3.1 – Safety study in pigmented DA rats, analysed one week post-
PBM 
3.3.1.1 ERG  
Overall, ERG parameters were unaffected by PBM, irrespective of the energy setting 
(Figure 3.4). Summaries of the b-wave and a-wave amplitudes are shown in Tables 3.1 
and 3.2, whilst the b-wave and a-wave implicit times are given in Tables 3.3 and 3.4. 
Paired Student’s t-test analysis revealed no statistical difference in b-wave amplitude in 
any of the treatment groups (baseline versus post-PBM). Similarly, paired Student’s t-
test analysis revealed no statistical difference in a-wave amplitude in any of the 
treatment groups (baseline versus post-PBM). The b-wave and a-wave implicit times 
were also not statistically significant in any of the treatment groups (baseline versus 
post-PBM).  
 
Table 3.1 Effect of PBM on b-wave amplitude 










Control 837.5 ± 185 868.9 ± 108.1 31.3 ± 44.9 0.54  
Sham 907.1 ± 111.6 917.9 ± 78.7 10.7 ± 51.1 0.84 
25 mW/cm2 825.0 ± 147.9 823.8 ± 89.1 -1.2 ± 53.2 0.98 
100 mW/cm2 903.6 ± 80.7 900.0 ± 96.4 -3.6 ± 47.1 0.94 
500 mW/cm2  941.0 ± 124.2 935.0 ± 95.5 -6.0 ± 33.7 0.86 
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Data are expressed as mean ± SEM, where n=6 (control), n=7 (sham), n=4 (25 
mW/cm2), n=7 (100 mW/cm2), n=10 (500 mW/cm2). 
 













Control 200.0 ± 91.9 225.0 ± 55.9 25.0 ± 27 0.42 
Sham 225.0 ± 55.9 203.6 ± 31.1 -21.4 ± 25.3 0.43 
25 mW/cm2 137.5 ± 41.5 156.3 ±  37 18.8 ± 31.3 0.59 
100 mW/cm2 196.4 ± 50.8 203.6 ±  38.8 7.1 ± 28.7 0.81 
500 mW/cm2  230.0 ± 72.3 207.5 ±  38.8 -23.0 ± 15 0.17 
Data are expressed as mean ± SEM, where n=6 (control), n=7 (sham), n=4 (25 
mW/cm2), n=7 (100 mW/cm2), n=10 (500 mW/cm2). 
 













Control 73.3 ± 1.3  75.0 ± 0.8 1.7 ± 0.9 0.16 
Sham 77.1 ± 2 78.0 ± 1.8 0.9 ± 0.8 0.21 
25 mW/cm2 76.5 ± 1.3 77.3 ± 2.5 0.8 ± 1 0.22 
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100 mW/cm2 76.6 ± 3.3 77.9 ± 1.3 1.3 ± 1.2 0.33 
500 mW/cm2  76.7 ± 2.3 77.9 ± 1.2 1.2 ± 0.9  0.19 
Data are expressed as mean ± SEM, where n=6 (control), n=7 (sham), n=4 (25 
mW/cm2), n=7 (100 mW/cm2), n=10 (500 mW/cm2). 
 













Control 20.3 ± 1.7 21.3 ± 1.7  1.0 ± 0.5  0.39 
Sham 22.0 ± 0.8 21.7 ± 0.8 -0.3 ± 0.5 0.57 
25 mW/cm2 21.5 ± 1 22.0 ± 1.1 0.5 ± 0.5 0.39 
100 mW/cm2 21.9 ± 0.7 21.6 ± 1 -0.3 ± 0.5 0.57 
500 mW/cm2  21.2 ± 0.8 21.2 ± 0.8 0.0 ± 0.4 0.99 
Data are expressed as mean ± SEM, where n=6 (control), n=7 (sham), n=4 (25 




Figure 3.4 Representative baseline and post-PBM ERG traces in the different 





Paired Student’s t-test analysis revealed no statistically significant difference between 
total retinal thickness at baseline versus 7 days post-PBM in any of the treatment groups 
(Table 3.5, Figure 3.5A); however, at the highest energy setting (500 mW/cm2), the 
mean total retinal thickness was 15.6 ± 6.9 µm thinner than at baseline, a difference that 
almost reached significance (P=0.051). Analysis of ONL thickness showed no 
statistically significant differences between ONL thickness at baseline versus 7 days 
post-PBM in the control, sham, 25 mW/cm2 and 100 mW/cm2 groups (Table 3.6, Figure 
3.5B). However, there was a statistically significant (P<0.05) difference in ONL 
thickness (-8.4 ± 3.7 µm; baseline versus 7 days post-PBM) in the 500 mW/cm2 group 
(Table 3.6, Figure 3.5B). Further analysis of ONL thickness of each of the eyes in the 
500 mW/cm2 group revealed significant differences (Table 3.7, Figure 3.6) in Rat 8 RE, 
Rat 11 RE, Rat 14 RE and Rat 16 RE which were also accompanied by fundus changes 
(Figure 3.7). The remaining eyes in the 500 mW/cm2 did not have any significant 
differences (Table 3.7) in ONL thickness before and 7 days after PBM laser.  
 















P value Fundus 
change 
(Yes/No) 
Control 250.2 ± 12.3 249.3 ± 11.5 -0.9 ± 0.5 0.11 No 
Sham 252.7 ± 8.6 252.2 ± 8.3 -0.5 ± 0.4 0.2 No 
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25 mW/cm2 258.6 ± 1.9 259.9 ± 3.9 1.3 ± 1.9 0.53 No 
100 mW/cm2 254.4 ± 5.8 254.2 ± 5.3 -0.2 ± 0.5 0.67 No 
500 mW/cm2  251.1 ± 9.5 235.7 ± 27.9 -15.6 ± 6.9 0.051 Yes 
Data are expressed as mean ± SEM, where n=6 (control), n=7 (sham), n=4 (25 mW/cm2), 
n=7 (100 mW/cm2), n=10 (500 mW/cm2). 
 















P value Fundus 
change 
(Yes/No) 
Control 51.4 ± 3.5 50.6 ± 2.4 -0.8 ± 0.6 0.21 No 
Sham 52.9 ± 3.2 52.5 ± 3.1 -0.4 ± 0.3 0.24 No 
25 mW/cm2 55.7 ± 4.4 55.0 ± 4.5 -0.7 ± 0.5 0.31 No 
100 mW/cm2 52.6 ± 3.6 51.8 ± 4.3 -0.8 ± 0.5 0.12 No 
500 mW/cm2  52.7 ± 2.7 44.3 ± 11.8 -8.4 ± 3.7 0.049* Yes 
Data are expressed as mean ± SEM, where n=6 (control), n=7 (sham), n=4 (25 
mW/cm2), n=7 (100 mW/cm2), n=10 (500 mW/cm2). *P<0.05 by Student’s paired t-test 
(baseline versus post-PBM). 
 
Table 3.7 Effect of PBM on ONL thickness of each 500 mW/cm treated DA rat eye 


















P value Fundus 
change 
(Yes/No) 
Rat 3 RE 52.8 ± 4.2 53.4 ± 5.1 -0.67 ± 2 0.74 No 
Rat 5 RE 57 ± 6.1 56.2 ± 6.1 -0.8 ± 2.6 0.77 No 
Rat 8 RE 53.7 ± 8.3 17.9 ± 11.4 -35.8 ± 4.2 <0.001*** Yes 
Rat 10 RE 45.4 ± 6.6 45.3 ± 5.6 -0.1 ± 2.6 0.97 No 
Rat 11 RE  49.7 ± 5 39.6 ± 12.8 -10.1 ± 4 <0.01** Yes 
Rat 12 RE 53.6 ± 6.5 54.1 ± 5.6 0.5 ± 2.6 0.19 No 
Rat 13 RE 53.7 ± 8.1 51.5 ± 6.9 -2.2 ± 3.2 0.5 No 
Rat 14 RE 53.8 ± 5.1 35.8 ± 15.1 -18 ± 4.6 <0.001*** Yes 
Rat 15 RE 52.9 ± 4.9 51.6 ± 4.7 -1.3 ± 2 0.52 No 
Rat 16 RE 53.2 ± 5.4 37.7 ± 10.1 -15.5 ± 3.3 <0.001*** Yes 




Figure 3.5 Effect of PBM on total retinal thickness (A) and ONL thickness (B) in DA 





Figure 3.6 Effect of PBM on each 500 mW/cm2 treated DA rat eye after 7 days. Data 
are expressed as mean ± SEM. **P<0.01, ***P<0.001 by Student’s paired t-test.  
 
Qualitative assessment of every sample revealed that none of the eyes from the control, 
sham, 25 mW/cm2 or 100 mW/cm2 groups displayed any abnormalities on SD-OCT or 
fundus imaging. This was not the case for the 500 mW/cm2 group. Four out of ten eyes 
(40%) in the 500 mW/cm2 group had noticeable fundus and SD-OCT changes at 7 days 
post-laser (see Figures 3.7-3.11, and Table 3.11). Evaluation of the fundus images of all 
four affected rats showed there to be marked pigment changes around the optic nerve 
head. The size of the affected area varied between rats, but it was always peripapillary 
and hence located within the centre of the irradiated area. On assessment of SD-OCT, 
there was localized damage mainly in the outer retina, specifically the ONL, which 
appeared thinned and disorganized. In the most severely affected eye (Figure 3.8), there 
was almost complete localised obliteration of the ONL and up to 40% reduction in total 
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retinal thickness compared to baseline. In contrast to the outer retina, the inner layers of 
each of the four affected eyes were morphologically normal. The slit lamp-delivered 
laser emits a collimated beam of 670 nm irradiation with a 4.5 mm diameter spot size on 
the retina. Hence, a substantial area of the entire rat retina receives irradiation. 
Excluding the peripapillary zone, no abnormalities were observed within the remainder 






Figure 3.7 Comparison of fundus photos taken at baseline and at 7 days post-PBM in 
four affected eyes that received 500 mW/cm2 PBM. Yellow arrows indicate 
abnormalities post-laser. 
 
Figure 3.8 Upper panel represents SD-OCT at baseline in DA rat 8 right eye (500 
mW/cm2) with point A marking total retinal thickness of 219 µm. Lower panel shows 
SD- OCT of the same rat 7 days post-laser. There is notable atrophy and a decrease in 
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total retinal thickness at point A to 132 µm - a 40% reduction from baseline. The ONL 
appears obliterated and almost unmeasurable. The outer plexiform player is not 
readily distinguishable. 
 
Figure 3.9 Upper panel represents SD-OCT at baseline in DA rat 11 right eye (500 
mW/cm2) with point A marking total retinal thickness of 271 µm and ONL thickness 
of 54 µm. Lower panel shows SD- OCT of the same rat 7 days post-laser. Total retinal 
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thickness and ONL thickness at point A are 181 µm (33% reduction) and 8 µm (85% 
reduction), respectively. 
 
Figure 3.10 Upper panel represents SD-OCT at baseline in DA rat 14 right eye (500 
mW/cm2) with point A marking total retinal thickness of 245 µm. Lower panel shows 
SD- OCT of the same rat 7 days post-laser. Total retinal thickness at point A is 178 
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µm (27% reduction). The ONL has been severely damaged and is unmeasurable post-
laser.  
 
Figure 3.11 Upper panel represents SD-OCT at baseline in DA rat 16 right eye (500 
mW/cm2) with point A marking total retinal thickness of 256 µm. Lower panel shows 
SD- OCT of the same rat 7 days post-laser. Total retinal thickness at point A is 176 
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µm (31% reduction). Post-laser, the ONL is too severely damaged at this point to 




Fluorescein angiograms taken of every eye from the control, sham, 25 mW/cm2, and 100 
mW/cm2 groups showed normal vasculature and no fluorescein leakage at 7 days post-
laser; however, 3/10 eyes (30%) treated with 500 mW/cm2 PBM displayed abnormal 
fluorescein leakage at 7 days post-laser (Figure 3.12, Table 3.8) that was present 
immediately upon injection of fluorescein, reached a peak after 15 minutes, plateaued 
until 20 minutes, before subsiding. The leakage is most likely to derive from deep within 
the retina, either at the deep capillary plexus or from the choroid. There were no other 
morphological vascular abnormalities.  
 
Table 3.8 FA characteristics of affected eyes treated with 500 mW/cm2 PBM 
Rat ID Days post-laser FA description 
DA rat 8 RE 7 Dense hyperfluorescence attributed to leakage 
noted inferior-nasally around the optic disc  
Dimensions: 2.6 x 0.9mm 
DA rat 14 RE 7 Cloudy hyperfluorescence superior to the optic 
nerve head 
Dimensions: 0.63 x 0.31mm 
DA rat 16 RE 7 Subtle leakage of fluorescein superior to the 
optic nerve head 





Figure 3.12 Top panel shows FA images of three affected eyes (500 mW/cm2) taken at 
7 days post-laser demonstrating varying levels of fluorescein leakage. Bottom panel 
represents FA images of sham treated eye that is normal. Images were captured 




Gross examination of whole eye specimens analysed at 7 days post-PBM showed no 
evidence of retinal haemorrhages or cataracts in eyes from any of the treatment groups.  
Histological evaluation of retinas from control, sham, 25 mW/cm2 (low dose), and 100 
mW/cm2 (medium dose) groups yielded results that were entirely consistent with those 
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obtained from SD-OCT and FA. Specifically, there was no evidence of photoreceptor 
destruction, disorganisation of photoreceptor segments, macro- or micro-gliosis, 
upregulation of stress proteins, or damage to the RPE, either within the peripapillary 
zone or throughout the remainder of the irradiated zone (see Figs. 3.14, 3.16, 3.17).  
 
Histological examination of rats treated with 500 mW/cm2 (high dose) confirmed the 
findings obtained from SD-OCT and FA. Thus, in a proportion of eyes (4/10; 
specifically DA 8R, DA 11R, DA 14R and DA 16R), localised peripapillary retinal 
damage was observed, but no obvious injury was manifest in the remainder of the 
irradiated zone (See Figs.  3.13-3.17). The affected rats (see Figs. 3.13 and 3.15 for 
representative images from DA rats 8R and 16R) featured very localised damage to the 
ONL with loss of photoreceptor nuclei as well as inner and outer segments. This was 
accompanied by localised upregulations of the stereotypical macroglial stress markers 
glial fibrillary acidic protein (GFAP) and ciliary neurotrophic factor (CNTF). 
Furthermore, an increased microglial presence was evident in the affected region, 
particularly in the degenerating outer nuclear layer. The RPE layer was mostly intact in 
the affected peripapillary zone, but individual areas of damage, or hypertrophy 
indicative of cell death and regeneration, could be discerned. The inner retina of affected 
rats remained structurally intact. Aside from the localised area of damage, minimal 
injury or glial responses could be observed in other areas around the ONH in four 
affected rats (see Figs. 3.16-3.17). Thus, in DA rat 16R for example, retinal injury is 
apparent immediately superior to the ONH, but not inferior to the ONH, nor at 1mm 
from the ONH in a superior or inferior direction. In the remaining 6/10 eyes, no 
88 
 
abnormalities were apparent either within the peripapillary zone or throughout the 






Figure 3.13 Histology of DA rat 8 right eye (500 mW/cm2). Transverse sections at the 
level of the optic nerve head (ONH) were stained for haematoxylin and eosin (A-D), 
and immunolabelled for GFAP (E-H), iba1 (I-L), CNTF (M-P) and RPE65 (Q-T). 
There is localised destruction of photoreceptor nuclei, inner and outer segments 
immediately inferior to the ONH (A, B, arrow). This is accompanied by greatly 
increased expression of GFAP (E, F, arrows) and CNTF (M, N, arrows) by Müller 
cells and astrocytes overlying and immediately adjacent to the affected area. Iba1-
positive activated microglia can be observed within the damaged area of the retina (I, 
J, arrows). The RPE layer appears relatively intact, but discrete areas of injury are 
apparent (Q, R, arrows, highlighted within insets). On the superior side of the ONH, 
there is no patent injury or upregulation of glial markers. Scale bar: A, C, E, G, I, K, 
M, O, Q, S = 250 µm; B, D, F, H, J, L, N, P, R, T = 50 µm. GCL, ganglion cell layer; 







Figure 3.14 Histology of DA rat 11 left eye (sham). Transverse sections at the level of 
the optic nerve head (ONH) were stained for haematoxylin and eosin (A-D), and 
immunolabelled for GFAP (E-H), iba1 (I-L), CNTF (M-P) and RPE65 (Q-T). There 
is no evidence of any abnormalities in any of the markers analysed. Scale bar: A, C, E, 
G, I, K, M, O, Q, S = 250 µm; B, D, F, H, J, L, N, P, R, T = 50 µm. GCL, ganglion cell 









Figure 3.15 Histology of DA rat 16 right eye (500 mW/cm2). Transverse sections at 
the level of the optic nerve head (ONH) were stained for haematoxylin and eosin (A, 
B), and immunolabelled for iba1 (C, D), GFAP (E, F), and RPE65 (G, H). Localised 
destruction of photoreceptor nuclei, inner and outer segments immediately superior to 
the ONH is evident (A, B, arrow). This is accompanied by greatly increased 
expression of GFAP (E, F, arrow) by Müller cells and astrocytes overlying and 
immediately adjacent to the affected area. Iba1-positive activated microglia can be 
observed within the degenerating ONL (C, D, arrow). The RPE layer appears intact, 
but some hypertrophy/cell regeneration is apparent (G, H, arrow, highlighted within 
inset). On the inferior side of the ONH, there is no patent injury or upregulation of 
glial markers. Scale bar: A, C, E, G = 250 µm; B, D, F, H = 50 µm. GCL, ganglion 






Figure 3.16 Effect of PBM on macroglia and microglia in DA rats at 7 days post-
PBM. (A-F) Representative images of normal retinas from sham, 100 mW/cm2 and 
damaged retina from the 500 mW/cm2 group immunolabelled for GFAP and iba1 
(arrows). Images were captured within the irradiated zone at approximately 1 mm 
from the optic nerve head. (G, H) Quantification of GFAP and iba1 abundances, as 
defined in the Materials and Methods. Data are expressed as the mean ± SEM, where 
n=6-10 for each group. ANOVA revealed no significant differences in GFAP or iba1 
abundance between treatment groups. Scale bar = 50 µm. GCL, ganglion cell layer; 





Figure 3.17 Effect of PBM on levels of stress proteins in DA rats at 7 days post-PBM. 
(A-F) Representative images of normal retinas from sham, 100 mW/cm2 and damaged 
retina from the 500 mW/cm2 group immunolabelled for CNTF and FGF-2 (arrows). 
Images were captured within the irradiated zone at approximately 1 mm from the 
optic nerve head. (G, H) Quantification of CNTF and FGF-2 abundances, as defined 
in the Materials and Methods. Data are expressed as the mean ± SEM, where n=6-10 
for each group. ANOVA revealed no significant differences in CNTF and FGF-2 
abundance between treatment groups. Scale bar = 50 µm. GCL, ganglion cell layer; 




3.3.2 Experiment 3.2 –Safety study in pigmented DA rats, analysed at three days 
post-PBM 
3.3.2.1 SD-OCT 
Paired Student’s t-test analysis revealed no statistically significant difference between 
total retinal thickness or ONL thickness at baseline versus 3 days post-PBM in any of 
the treatment groups (Tables 3.9, 3.10; Figure 3.18). Nevertheless, 2/6 eyes (33%) at the 
highest energy setting (500 mW/cm2) showed noticeable fundus and SD-OCT changes 
at the 3 day time point (Figures 3.19-3.21), which were similar to those documented at 
the 7 day endpoint. 
 















P value Fundus 
change 
(Yes/No) 
Sham 55.9 ± 1.9 55.3 ± 1.7 -0.6 ± 0.4 0.25 No 
100 mW/cm2 55.7 ± 3.9 56.4 ± 4.1 -0.7 ± 0.3 0.16 No 
500 mW/cm2  56.4 ± 2.3 52.6 ± 4.7 -3.9 ± 2.8 0.22 Yes 
Data are expressed as mean ± SEM, where n=3 (sham), n=3 (100 mW/cm2), n=6 (500 
mW/cm2). 
 

















P value Fundus 
change 
(Yes/No) 
Sham 55.9 ± 1.9 55.3 ± 1.7 -0.6 ± 0.4 0.25 No 
100 mW/cm2 55.7 ± 3.4 56.4 ± 4.1 0.7 ± 0.3 0.16 No 
500 mW/cm2  56.4 ± 2.3 52.6 ± 4.7 -3.8 ± 2.8 0.22 Yes 





Figure 3.18 Effect of PBM on total retinal thickness (A) and ONL thickness (B) in 




Figure 3.19 Comparison of fundus photos taken at baseline and at 3 days post-PBM 







Figure 3.20 Upper panel represents SD-OCT at baseline in DA rat 19 right eye (500 
mW/cm2) with point A marking total retinal thickness of 263 µm. Lower panel shows 
SD- OCT of the same rat 3 days post-laser. Total retinal thickness at point A is 202 




Figure 3.21 Upper panel represents SD-OCT at baseline in DA rat 20 right eye (500 
mW/cm2) with point A marking total retinal thickness of 240 µm. Lower panel shows 
SD- OCT of the same rat 3 days post-laser. Total retinal thickness at point A is 217 





Fluorescein angiograms taken of every eye from the sham, 100 mW/cm2 and 500 
mW/cm2 groups showed normal vasculature and no fluorescein leakage at 3 days post-
laser, including the two eyes from the 500 mW/cm2 group that had peripapillary 
abnormalities as evidence by SD-OCT and fundus photography (Figure 3.22). 
 
 
Figure 3.22 FA images of the right eyes of DA rats 19 and 20 taken at 3 days post-
laser, which appear normal despite having fundus and SD-OCT changes. 
 
3.3.2.3 Histology 
Gross examination of whole eye specimens analysed at 3 days post-PBM showed no 
evidence of retinal haemorrhages or cataracts in eyes from any of the treatment groups.  
Histological evaluation of retinas from sham and 100 mW/cm2 groups yielded results 
that were entirely consistent with those obtained from SD-OCT and FA. Specifically, 
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there was no evidence of photoreceptor destruction, disorganisation of photoreceptor 
segments, macro- or micro-gliosis, upregulation of stress proteins, or damage to the RPE, 
either within the peripapillary zone or throughout the remainder of the irradiated zone 
(see Figs. 3.24-3.26).  
  
Histological examination of rats treated with 500 mW/cm2 (high dose) confirmed the 
findings obtained from SD-OCT and FA. Thus, in 2/6 eyes (DA 19R and DA 20R), 
localised peripapillary retinal damage was observed, but no neuronal injury was 
manifest in the remainder of the irradiated zone (See Figs. 3.23, 3.25, 3.26). The 
affected rats (see Figs. 3.23 for representative images from DA rat 19R) featured very 
localised damage to the ONL with loss of photoreceptor rod and cone nuclei, inner and 
outer segments. This was accompanied by localised upregulations of the stereotypical 
macroglial stress markers glial fibrillary acidic protein (GFAP) and ciliary neurotrophic 
factor (CNTF). Furthermore, a dramatically increased microglial presence was evident 
in the affected region, particularly in the degenerating outer nuclear layer. Overt damage 
to the RPE layer could be discerned. The inner retina of affected rats remained 
structurally intact. As for the 7d rats, the peripapillary damage was very localised (See 
Fig. 3.23). Unlike the 7d rats, subtle stress responses, such as GFAP and FGF-2 
upregulations, could be observed 1 mm from the ONH on the affected side, a distance 
well within the irradiated zone (See Figs. 3.25, 3.26). In the remaining 4/6 eyes, no 
abnormalities were apparent either within the peripapillary zone or throughout the 






Figure 3.23 Histology of DA rat 19 right eye (500 mW/cm2). Transverse sections at 
the level of the optic nerve head (ONH) were stained for haematoxylin and eosin (A-
C), and immunolabelled for GFAP (D-F), iba1 (G-I), CNTF (J-L), cone arrestin 
(cone arres, M-O) and RPE65 (P-R). There is localised destruction of photoreceptor 
rod and cone nuclei, inner and outer segments immediately superior to the ONH (A, 
B, M, N arrows). This is accompanied by greatly increased expression of GFAP (D, E, 
arrows) and CNTF (J, K, arrows) by Müller cells and astrocytes overlying and 
immediately adjacent to the affected area. Numerous iba1-positive, activated 
microglia can be observed within the damaged area of the retina (G, H, arrows). The 
RPE layer shows loss of RPE65 immunolabelling at the lesion (Q, arrows, highlighted 
within insets). On the inferior side of the ONH, there is no patent injury or 
upregulation of glial markers (C, F, I, L, O, R). Scale bar: A, D, G, J, M, P = 250 µm; 
B, C, E, F, H, I, K, L, N, O, Q, R = 50 µm. GCL, ganglion cell layer; INL, inner 







Figure 3.24 Histology of DA rat 21 left eye (100 mW/cm2). Transverse sections at the 
level of the optic nerve head (ONH) were stained for haematoxylin and eosin (A-C), 
and immunolabelled for GFAP (D-F), iba1 (G-I), CNTF (J-L), cone arrestin (cone 
arres, M-O) and RPE65 (P-R). There is no discernible injury to rod or cone 
photoreceptor nuclei, nor to inner and outer segments either superior or inferior to 
the ONH (A-C, M-O). This is no upregulation of GFAP (D-F) or CNTF (J-L) by 
Müller cells or astrocytes. There is no obvious increase in the number of iba1-positive 
microglia nor do they display any morphological signs of activation (G, H, arrows). 
The RPE layer appears normal on both sides of the ONH (P-R arrows, highlighted 
within insets). Scale bar: A, D, G, J, M, P = 250 µm; B, C, E, F, H, I, K, L, N, O, Q, R 
= 50 µm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear 




Figure 3.25 Effect of PBM on macroglia and microglia in DA rats at 3 days post-
PBM. (A-F) Representative images of retinas from sham, 100 mW/cm2 and 500 
mW/cm2 groups immunolabelled for GFAP and iba1 (arrows). Images were captured 
within the irradiated zone at approximately 1 mm from the optic nerve head. (G, H) 
Quantification of GFAP and iba1 abundances, as defined in the Materials and 
Methods. Data are expressed as the mean ± SEM, where n=3-6 for each group. 
ANOVA revealed no significant differences in GFAP or iba1 abundance between 
treatment groups. Nevertheless, there was a tendency for elevated GFAP abundance 
in the 500 mW/cm2 group. Scale bar = 50 µm. GCL, ganglion cell layer; INL, inner 





Figure 3.26 Effect of PBM on levels of stress proteins in DA rats at 3 days post-PBM. 
(A-F) Representative images of retinas from sham, 100 mW/cm2 and 500 mW/cm2 
groups immunolabelled for CNTF and FGF-2 (arrows). Images were captured within 
the irradiated zone at approximately 1 mm from the optic nerve head. (G, H) 
Quantification of CNTF and FGF-2 abundances, as defined in the Materials and 
Methods. Data are expressed as the mean ± SEM, where n=3-6 for each group. 
ANOVA revealed no significant differences in CNTF and FGF-2 abundance between 
treatment groups. Nevertheless, there was de novo FGF-2 expression by 
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photoreceptors in rat 20R from the 500 mW/cm2 group (see F). Scale bar = 50 µm. 
GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. 
 
Table 3.11 Summary of affected 500 mW/cm2 treated DA rats with SD-
OCT/fundus changes 























238.9 ± 7.8 175.9 
±19.4 
53.7 ± 8.3 17.9 ± 11.4 Distinct retinal pigment changes around the optic 
disk, particularly inferior nasally on fundus 
imaging. On SD-OCT, there were points of 
severe damage with reduction of total retinal 




253.9 ± 7.2 223.9 
±10.2 
49.7 ± 5.0 39.6 ± 12.8 Fundus imaging shows notable pigment changes 
from the adjacent temporal side of the optic disk 
extending superiorly.  On SD-OCT, there is up to 
33% and 85% reduction of total retinal thickness 





249.7 ± 8 218 ± 14.3 53.8 ± 5.1 35.8 ± 15.1 There is marked pigment changes surrounding 
the temporal and superior side of the optic disk 
on fundus imaging. SD-OCT shows a decrease of 
up to 27% total retinal thickness as well as 






239 ± 5.9 212.4 ± 
12.7 
53.2 ± 5.5 37.7 ± 10.1 Fundus imaging reveals two confluent spots of 
pigment change- one larger area situated 
superiorly while a smaller area located superior-
temporally relative to the optic disk. On SD-
OCT, there is a reduction of total retinal 
thickness of 31% whilst the ONL is severely 




266 ± 6.7 247.4 ± 18 59.4 ± 10.7 48.3 ± 16.6 There are subtle pigment changes superiorly to 
the optic disk. On SD-OCT, there is 23% 
reduction of total retinal thickness and 




252.9 ± 9.3 239.8 ± 
16.7 
59 ± 10.4 45.2 ± 19 Fundus imaging again subtle pigment changes 
superior-nasally to the optic disk. There is 
relatively minor thinning of the total retinal 
thickness (10%). However, the ONL thickness 
immeasurable in these damaged areas. 
 
 




No qualitative changes were observed in the SD rat retina at 7 days post-laser. Neither 
the total retinal nor ONL thickness were significantly different between baseline and 



















P value Fundus 
change 
(Yes/No) 
Sham 231.6 ± 2.8 232.5 ± 1.8 0.9 ± 0.7 0.33 No 
100 mW/cm2 
dose 
232.0 ± 3.6 232.4 ± 5.5 0.4 ± 1.4 0.83 No 
500 mW/cm2 236.3 ± 5.8 235.5 ± 4.4 -0.8 ± 0.7 0.60 No 
Data are expressed as mean ± SEM, where n=3 (sham), n=3 (100 mW/cm2), n=6 (500 
mW/cm2). 
 















P value Fundus 
change 
(Yes/No) 
Sham 55.7 ± 3.9 54.9 ± 2 -0.7 ± 0.3 0.25 No 
100 mW/cm2  55.4 ± 0.6 56 ± 0.8 0.6 ± 1 0.66 No 
500 mW/cm2  53.1 ± 2 53.6 ± 1.8 0.5 ± 0.6 0.39 No 





Figure 3.27 Effect of PBM on total retinal thickness (A) and ONL thickness (B) in SD 
rats after 7 days. Data are expressed as mean ± SEM. 
 
3.3.3.2 FA 
SD rat eyes showed normal FA with no evidence of fluorescein leakage in any of the 





Gross examination of whole eye specimens analysed at 7 days post-PBM showed no 
evidence of retinal haemorrhages or cataracts in eyes from any of the SD treatment 
groups. 
  
Unlike DA rats, at the high energy setting (500 mW/cm2), there was no focal damage 
noted within the peripapillary zone in any of the 6 rats analysed (Fig. 3.28). All retinal 
layers were intact. No injury to the ONL, inner or outer segments was discernible. There 
was no upregulation of glial stress markers or damage to the RPE. Similarly, at 1 mm 
from the ONH, within the irradiated zone, there were no differences in the abundances 






Figure 3.28 Histology of SD rat 26 right eye (500 mW/cm2). Transverse sections at the 
level of the optic nerve head (ONH) were stained for haematoxylin and eosin (A-C), 
and immunolabelled for GFAP (D-F), iba1 (G-I), CNTF (J-L), cone arrestin (cone 
arres, M-O) and RPE65 (P-R). There is no discernible injury to rod or cone 
photoreceptor nuclei, nor to inner and outer segments either superior or inferior to 
the ONH (A-C, M-O). This is no upregulation of GFAP (D-F) or CNTF (J-L) by 
Müller cells or astrocytes. There is no obvious increase in the number of iba1-positive 
microglia nor do they display any morphological signs of activation (G, H, arrows). 
The RPE layer appears normal on both sides of the ONH (P-R arrows, highlighted 
within insets). Scale bar: A, D, G, J, M, P = 250 µm; B, C, E, F, H, I, K, L, N, O, Q, R 
= 50 µm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear 




Figure 3.29 Effect of PBM on macroglia and microglia in SD rats at 7 days post-PBM. 
(A-F) Representative images of retinas from sham, 100 mW/cm2 and 500 mW/cm2 
groups immunolabelled for iba1 and GFAP. Images were captured within the 
irradiated zone at approximately 1 mm from the optic nerve head. (G, H) 
Quantification of iba1 and GFAP abundances, as defined in the Materials and 
Methods. Data are expressed as the mean ± SEM, where n=3-6 for each group. 
ANOVA revealed no significant differences in GFAP or iba1 abundance between 
treatment groups. Scale bar = 50 µm. GCL, ganglion cell layer; INL, inner nuclear 




Figure 3.30 Effect of PBM on levels of stress proteins in SD rats at 7 days post-PBM. 
(A-F) Representative images of retinas from sham, 100 mW/cm2 and 500 mW/cm2 
groups immunolabelled for CNTF and FGF-2 (arrows). Images were captured within 
the irradiated zone at approximately 1 mm from the optic nerve head. (G, H) 
Quantification of CNTF and FGF-2 abundances, as defined in the Materials and 
Methods. Data are expressed as the mean ± SEM, where n=6-10 for each group. 
ANOVA revealed no significant differences in CNTF and FGF-2 abundance between 
treatment groups. Scale bar = 50 µm. GCL, ganglion cell layer; INL, inner nuclear 




3.4.1 Laser-delivered PBM is safe in albino rats and at doses of 100 mW/cm2 
in pigmented rats 
The results from this chapter reveal that there exists a safety threshold for laser-
delivered PBM in pigmented rats, which could be identified as 500 mW/cm2 irradiance 
or 45 J/cm2 fluence (see section 3.4.2). However, at irradiance doses of up to 100 
mW/cm2, PBM caused no adverse changes to the pigmented retina, as determined by 
fundus photography, SD-OCT, FA, electroretinography, and immunohistochemical 
assessment of neuronal and glial markers. In albino rats, no adverse events were 
identified even at 500 mW/cm2 irradiance; there were no structural changes identified 
post-laser using any of the methods identified above. Furthermore, there was no 
upregulation of GFAP within the irradiated zone. GFAP, a cytoskeletal protein produced 
by macroglial cells, is generally considered the most sensitive indicator of retinal 
stress.207  
 
3.4.2 Laser-delivered PBM causes occasional localised damage at 500 
mW/cm2 in pigmented rats 
At the highest irradiance dose (500 mW/cm2), occasional localized damage was noted in 
pigmented rats within the peripapillary region. This was clearly identifiable by SD-OCT, 
FA and histological changes post-laser when compared to baseline. Changes were 
evident by 3 days following the last laser session and were still present at 7 days post-
laser. Damage was confined to the outer retina, encompassing the ONL, inner and outer 
segments, and RPE. SD-OCT changes corresponded well with histological degenerative 
121 
 
changes found in photoreceptor nuclei, inner and outer segments. Moreover, in affected 
rats, there were marked increases of damage markers at the site of injury, including 
evidence of macro- (GFAP) and micro-gliosis (iba1 microglial cells), as well as glial-
derived stress proteins (CNTF and FGF-2). These are common immunohistochemical 
markers for homeostatic dysfunction and are therefore sensitive markers for retina 
injury.208 CNTF and FGF-2, in particular, are trophic factors upregulated as part of the 
retina’s endogenous survival mechanism against injuries including light damage, trauma, 
ischemia, excitotoxicity and laser-induced damage.208-212 Of importance, upregulation of 
these histological markers were confined to the peripalliary zone. Only very occasional 
effects were observed at distances of 1 mm from the ONH, which remains well within 
the zone of irradiation. At 1 mm from the ONH, there were no statistically significant 
increases in expression of GFAP, iba1, CNTF or FGF-2 between the sham and 500 
mW/cm2 groups, indicating the absence of any overt homeostatic disruption. It is 
important to emphasize that the quantification of immunohistochemistry was only 
performed away from the optic nerve head. As there was no difference between affected 
and unaffected rats in the 500 mW/cm2 group away from the nerve head, there was no 
need to subdivide analysis. 
 
On SD-OCT, retinal changes appeared more prominent at 7 days post-laser, which was 
manifest as greater total retinal thickness loss compared to 3 days post-laser. This 
suggests an evolving loss of photoreceptors in the affected area. Interestingly, the 
significant difference in ONL thickness before and 7 days-post laser in the 500 mW/cm2 
seems largely driven by very severe thinning in the affected animals- Rats 8 RE, Rat 11 
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RE, Rat 14 RE and Rat 16RE (Table 3.11), causing the mean post-PBM ONL thickness 
to be significantly lower. In contrast to affected rats at 7 days post-laser, affected rats 
analysed at 3 days post-laser did not demonstrate FA changes, despite having clear 
histological and SD-OCT evidence of focal damage. One explanation for this finding is 
that inflammatory changes post-laser cause a delayed effect upon the deep vessels of the 
retina or choroidal vessels, causing leakage that may not be visible initially. Due to the 
focal nature of damage, it is worthy to mention that changes in retinal thickness may be 
underestimated by the measurement of the pre-determined SD-OCT analysis points 
which may miss particular areas of focal thinning. In hindsight, these pre-determined 
analysis points were selected to reflect generalized changes within the irradiation zone 
rather than focal changes which were not anticipated. We acknowledge that there may 
be slight variations measurements on retinal thinning before and after treatment due to 
the slight differences in the angle of scans captured. This was minimized by 
corresponding measurement points to landmarks such as vessels to ensure the same 
point was measured before and after treatment. Despite SD-OCT, histology and FA 
showing damage in some pigmented rats treated with 500 mW/cm2 PBM, no significant 
changes in b- or a-wave amplitude or implicit times were measurable on ERG. A likely 
reason for this finding is that ERG detects global visual changes reflecting pan-retinal 
damage. The focal damage observed in these rats may well have been detectable on 
multifocal ERG.213  It is a limitation of the current study that multifocal ERG was not 
available. Another potential minor confounding factor is the presence of oscillatory 
potentials that may impact measurements of implicit time and b-wave amplitudes. The 
use of a low pass filter may address this. On another note, it is worthy to mention the 
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reason for the use of rats instead of mice in the current safety study was that dilated 
mice eyes could only sufficiently receive up to 100 mW/cm2 hence rat eyes were 
required to examine the 500 mW/cm2 irradiance dose. 
 
The mechanism behind the localised damage seen following high dose, laser-delivered 
PBM is presently unknown. One putative explanation is that it may be a manifestation 
of PBM’s biphasic dose response. This phenomenon is based on the premise that a dose 
too low will not produce benefit, however, too high a dose may suppress PBM’s 
positive influence or even cause damage. Therefore, the efficacy of PBM relies on 
determining an optimal dose. The biphasic dose response nature of PBM is a well-
documented phenomenon.177 Indeed, Chu-Tan et al.188 reported a biphasic dose response 
of 670 nm LED in a light-induced retinal degeneration rat model. The irradiance was 
fixed at 60 mW/cm2 whilst a fluence range of 9-90 J/cm2 was assessed on varying 
severities of light-induced retinal injuries. At low to medium damage setting, low dose 
PBM fluence provided neuroprotective benefit, whilst 90 J/cm2 was ineffective and even 
increased photoreceptor apoptosis. Interestingly, in eyes with high damage, only 90 
J/cm2 was beneficial, suggesting higher doses may be required for more severe injuries. 
Most retinal degeneration animal studies have used an irradiance range of 20-60 
mW/cm2 or fluence range of 3.4-9 J/cm2 and have not reported any adverse effects of 
PBM.137,163,164,189-192 The high dose tested in our study is well above previous safe 
fluence ranges. PBM is known to upregulate ROS in normal tissues in a dose-dependent 
manner whilst reducing ROS during oxidative stress.165,185 Conceivably, higher doses in 
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affected rats may lead to excess ROS that overwhelms the intrinsic cellular antioxidant 
system and result in oxidative damage.   
 
An alternative explanation for the focal damage is that it may be laser-induced. The 
mechanisms underlying laser-induced damage are photochemical, photomechanical and 
photothermal.214 Photochemical damage is caused by free radicals that are generated 
following interaction of high-energy, shorter wavelength visible light with chromophore 
molecules contained within the retina and RPE. The free radicals attack nearby cellular 
structures causing lipid and protein peroxidation particularly lipid rich POS and protein-
rich neurosensory retina. Photochemical damage is associated with increased exposure 
duration, accumulative doses and progressive retinal degeneration.215 Given the PBM 
laser emits a longer wavelength 670 nm light, a photochemical cause is unlikely. In 
addition, the neurosensory retina, which appeared unaffected in the study, would also 
have been expected to be damaged by protein oxidation. Varying the duration and the 
number of sessions in further studies may provide a clue as to whether a photochemical 
component is present.  
 
Photomechanical damage results from mechanical compressive or tensile forces 
produced by the rapid introduction of energy into the RPE melanosomes.216 In the 
present study, photomechanical damage is unlikely given that it requires both an 
enormous irradiance doses in the range of megawatts or terawatts per cm squared as 




Photothermal damage derives from photon absorption by tissue molecules causing 
increased mean kinetic energy which is dissipated by molecules colliding, resulting in a 
temperature rise.214 Generally, the wavelength is inversely proportional to the potential 
increase of kinetic energy and subsequent temperature rise for a given exposure time. 
Photon absorption is facilitated by pigments, including melanin, which is most abundant 
in the RPE. Pigmented rats have higher melanin in their RPE and are thus much more 
susceptible to photothermal laser damage than albino rats. Photothermal damage is 
initially evident histologically in photoreceptors and the RPE which is consistent with 
the focal damage observed in the affected rats of this study.215,217,218 Of the various 
theoretical possibilities, photothermal damage would seem to be the most likely 
mechanism of laser-induced injury, due to the distribution and scale of damage and the 
fact that only pigmented rats were affected. However, it is worth noting that the PBM 
laser has a flat-top beam profile and thus broader damage would have been expected 
within the irradiance zone with photothermal injury.  
 
The results from the present study indicate that there exists a safety threshold for PBM 
laser which was identified as 500 mW/cm2 irradiance or 45 J/cm2 fluence for pigmented 
rats. The findings have some resemblance to those of a long-term safety study of 
transcranial laser-delivered 808 nm PBM on SD rat brain that reported photothermal 
damage with continuous wave laser at irradiances of 750 mW/cm2 (90 J/cm2 fluence).219 
Rats treated with PBM of up to 375 mW/cm2 irradiance were unaffected. Histological 
analysis of affected brain tissue at the high setting revealed focal areas characterized by 
subdural necrosis, loss of neuronal tissue, infiltration of macrophages, foci of granular 
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mineralization and meningeal artery degeneration that were consistent with thermal 
damage. These rats displayed thermal-related skin reddening and blistering in irradiated 
areas in addition to neurological deficits.  
 
Safe treatment parameters from preclinical studies are often difficult to extrapolate to 
the clinical setting due to variation of delivery methods, wavelength and physiological 
differences between targeted tissues. The rationale for the current study was to precisely 
examine safe PBM dosages for treatment of the retina with a novel laser prior to 
assessment of neuroprotection efficacy and eventual clinical translation. There have 
been clinical safety studies of PBM laser in stroke220,221 and hair loss222, but very few 
studies targeting application to the retina. The most notable exception is that study of Al 
Kent et al.223, who performed a clinical study to examine the safety of PBM in neonates 
with retinopathy of prematurity using 670 nm light at 9 J/cm2 for 15 minutes (10 
mW/cm2). There were no adverse effects reported, however, a non-confluent LED 
source was used and the primary outcomes were skin-related rather than eye-associated 
adverse effects. Thus, the results have little relevance to the current study.  
 
There is little doubt that laser is a highly suitable delivery method for PBM as it allows 
for direct exposure of calculated irradiances to to the retina, avoiding random scattering 
of R/NIR light that comes from non-coherent LED-based PBM. In addition, the laser 
device, which is mounted on a slit-lamp, provides the advantage of immediate 
translation to the clinical setting, as the setup would be familiar to clinicians due to its 





The PBM laser is safe at low and medium irradiation doses, however, in some 
pigmented rats, very localised damage were noted at the high irradiance dose setting 
(500 mw/cm2). The study findings reflect a safety threshold for PBM, facilitating the use 




4.  Neuroprotection efficacy of laser-delivered 
photobiomodulation in a mouse model of retinitis pigmentosa 
 
4.1 Aims 
The aims of the experiments detailed in chapter 4 were as follows: 1) to characterize the 
populations of genuine short wavelength opsin sensitive (S-opsin+) cones, genuine 
medium/long wavelength opsin sensitive (M/L-opsin+) cones, and dual cones (cones that 
express both S-opsin and M/L-opsin) in the four retinal quadrants of 60 day old rd1 
mice; 2) to investigate whether laser-directed PBM augments cone photoreceptor 
survival in rd1 mice using the safe irradiance settings identified from Chapter 3.  The 
hypothesis to be tested was that laser-delivered PBM promotes survival of S-opsin+ and 
M/L-opsin+ cones in rd1 mice. 
 
4.2 Design 
4.2.1 Characterization study 
The rd1 mice is a well-known rodent model for autosomal RP, characterized by rapid 
rod loss starting from P8-10 and finishing at P21.76 However, to our knowledge there are 
no studies that have characterized the ratio of different cone types in this animal model. 
The rationale for this study was to characterize the cone population in the rd1 mice. 
Such information would provide important baseline data for the subsequent 
neuroprotection study. Rd1 eyes (N=24) at P60 from control animals were collected and 
dissected for immunohistochemical analysis (Figure 4.1). Whole-mount retinae were 
double labelled with OPN1SW and anti-R/G opsin. OPN1SW labels ultraviolet sensitive 
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opsin expressed by S-opsin+ cones. Anti-R/G opsin labels red and green sensitive M/L-
opsin expressed by M/L-opsin+ cones. Dual cones express both S-opsin and M/L-opsin. 
Quantification was performed according to the Methods detailed in Chapter 2. 
 
4.2.2 Neuroprotection study 
Rd1 mice were divided into three treatment groups: sham, low dose PBM (25mW/cm2) 
and high dose PBM (100mW/cm2). In each animal, one eye received sham or PBM, 
while the fellow eye was untreated.  Treatment began from P21 and occurred every 
twice weekly until euthanasia. Optokinetic (OKN) function was assessed at P35 by 
determining maximal spatial frequency for a positive head reflex. Animals were 
euthanized at P60 (experiment 4.2a- Figure 4.2) or P90 (experiment 4.2b- Figure 4.3) 
and the retinas dissected for determination of cone survival. The densities of S-opsin+ 
cones and M/L-opsin+ cones were determined following fluorescent double 
immunolabelling of retinal wholemounts (Figure 4.10, 4.14). In addition, cone segment 
density was separately determined.  Cone segments were identified by their narrow 
bundle-like appearance and labelled with greater fluorescent intensity (Fig. 4.18). To 
assess the cone segment density, the threshold was adjusted so that only segments were 















Figure 4.3: Flow chart of the experimental plan for experiment 4.2b 
 
4.2.3 Laser procedure 
Mice were sedated with isofluorane throughout the laser procedure. One drop of a local 
anaesthetic (oxybuprocaine 0.4%) and one drop of a pupil dilator (tropicamide 1%) to 
enable opening of the pupil and visualisation of the optimum area of retina through the 
eye. Mice were anaesthetised using isofluorane throughout the procedure. The mice was 
placed on a custom-designed rodent holder by the researcher at the slit lamp laser 
133 
 
delivery system. The laser was centred on the optic nerve and the retina was exposed to 
R/NIR irradiation for 90 seconds. 
 
4.3 Results 
4.3.1 Characterization of cone populations 
The mean cone population of rd1 mice composed 59.07% S-opsin+ cones, 14.01 M/L-
opsin+ cones and 26.92% dual cones (Figure 4.8). In the superior retina, the mean cone 
population comprised 8.23% S-opsin+ cones, 38.1% M/L-opsin+ cones and 53.67% dual 
cones (Figure 4.4, 4.9A). In the inferior retina, M/L-opsin+ cones were absent whilst S-
opsin+ cones and dual cones accounted for 97.71% and 2.29% of the cone population, 
respectively (Figure 4.5, 4.9B). In the nasal retina (Figure 4.6, 4.9C), the mean cone 
population comprised 30.16% S-opsin+ cones, 23.59% M/L-opsin+ cones and 46.25% 
dual cones. The mean cone population in the temporal retina (Figure 4.7, 4.9D) 




Figure. 4.4 Double-labelled immunofluorescence photomicrograph of rd1 superior 
retina. (A) shows OPNSW1 labelled S-opsin+ cones,( D) shows masked S-opsin+ cones 
and (G) represent overlay image. (B) shows anti-R/G opsin labelled M/L-opsin+ cones , 
(E) shows masked M/L-opsin+ cones and (H) represents overlay image. (C) shows 
dual cones from a composite merged image of S-opsin+ and M/L-opsin+ cones. (F) 




Figure 4.5 Double-labelled immunofluorescence photomicrograph of rd1 inferior 
retina. (A) shows OPNSW1 labelled S-opsin+ cones,( D) shows masked S-opsin+ cones 
and (G) represent overlay image. (B) shows anti-R/G opsin labelled M/L-opsin+ cones , 
(E) shows masked M/L-opsin+ cones and (H) represents overlay image. (C) shows 
dual cones from a composite merged image of S-opsin+ and M/L-opsin+ cones. (F) 




Figure 4.6 Double-labelled immunofluorescence photomicrograph of rd1 nasal retina. 
(A) shows OPNSW1 labelled S-opsin+ cones,( D) shows masked S-opsin+ cones and 
(G) represent overlay image. (B) shows anti-R/G opsin labelled M/L-opsin+ cones , (E) 
shows masked M/L-opsin+ cones and (H) represents overlay image. (C) shows dual 
cones from a composite merged image of S-opsin+ and M/L-opsin+ cones. (F) shows 




Figure 4.7 Double-labelled immunofluorescence photomicrograph of rd1 temporal 
retina. (A) shows OPNSW1 labelled S-opsin+ cones,( D) shows masked S-opsin+ cones 
and (G) represent overlay image. (B) shows anti-R/G opsin labelled M/L-opsin+ cones , 
(E) shows masked M/L-opsin+ cones and (H) represents overlay image. (C) shows 
dual cones from a composite merged image of S-opsin+ and M/L-opsin+ cones. (F) 





Figure 4.8 Bar graph displaying mean composition of cone population in rd1 mice 




Figure. 4.9 Bar graphs displaying composition of the cone population in the superior 






4.3.2 Effect of photobiomodulation on survival of S-opsin+ cones at P60 
Compared to control (n=31) and sham (n=10) animals, the PBM-treated 25 mW/cm2 
(n=10) and 100 mW/cm2 (n=11) groups had significantly greater (P<0.001) S-opsin+ 
cone density at P60 (Figure 4.10, 4.11). There was no significant difference in cone 
density between 25 mW/cm2 and 100 mW/cm2 group (P=0.99).  
Analysis of the distribution of S-opsin+ cones at P60 revealed significantly (P<0.001) 
higher cone densities in both the inferior and superior quadrants of the retina in both 
PBM groups when compared to control or sham-treated mice (Figure 4.12A, B). 
Furthermore, there were significantly (P<0.001) higher cone densities in both the central 
and peripheral regions of the retina in both PBM groups when compared to control- or 
sham-treated mice (Figure 4.12C, D). When normalised (on a pairwise basis) to the 
control left eyes, S-opsin-+ cones displayed a trend to greater protection in the superior 
retina versus the inferior retina in all treatment groups (25 mW/cm2, 100 mW/cm2); 
however this was not statistically significant (P=0.79 for 25 mW/cm2; P=0.13 for 100 
mW/cm2) (Figure 4.13A). When normalised (on a pairwise basis) to the control left eyes, 
preservation of S-opsin-+ cones was significantly greater in the peripheral retina versus 
the central retina in both the 25 mW/cm2 (P<0.01) and 100 mW/cm2 PBM (P<0.05) 




Figure 4.10 Representative immunofluorescent photomicrographs of rd1 (P60) retinal 
wholemounts labelled with OPNSW1 from the sham, 25 mW/cm2 and 100 mW/cm2 
groups. Images shown are from the central and peripheral portions of the superior 






Figure 4.11 Boxplot representation of mean S-opsin+ cone density at P60 in the 
control, sham, 25 mW/cm2 and 100 mW/cm2 groups. Results were analyzed by 
ANOVA with Tukeys’ multi-comparison test (***P<0.001). Black stars against 
control, green stars against sham.  Error bars represent 1.5 times the 1st and 3rd 




Figure 4.12 Boxplot representation of the spatial distribution of S-opsin+ cone density at 
P60 in the inferior retina (A), superior retina (B), central retina (C) and peripheral retina 
(D). Results were analyzed by ANOVA analysis with post-Tukey’s comparison test 
(***P=<0.001). Black stars against control, green stars against sham. Error bars 






Figure 4.13 Bar graphs displaying comparative regional efficacy of neuroprotection 
of S-opsin+-cones at P60 as a percentage of control for superior vs inferior retina (A) 
and peripheral vs central retina (B). Data represent mean±SEM. Results were 





4.3.3 Effect of photobiomodulation on survival of M/L-opsin+ cones at P60  
The data produced in the characterization study of the distribution of different cone 
types at P60 in the rd1 strain (section 4.3.1) reveals that M/L-opsin+ cone survival in the 
inferior retina was negligible. As such, throughout the neuroprotection experiments, 
M/L-opsin+ cone survival was quantified in the superior, nasal and temporal quadrants 
of the retina, but not in the inferior retina. PBM treated 25 mW/cm2 (P<0.001, n=8) and 
100 mW/cm2 groups (P<0.001, n=9) had significantly higher M/L-opsin+ -cone density 
at P60 compared to the control (n=24) and sham (n=7) groups (Figures 4.14, 4.15). 
There was, however, no significant difference between the 25 mW/cm2 and 100 
mW/cm2 group (P=0.33).  
 
Analysis of the distribution of M/L-opsin+ cones at P60 revealed that, when compared to 
controls, the 25 mW/cm2 group had significantly (P<0.001) higher M/L-opsin+ cone 
density in the superior (P<0.001), peripheral (P<0.001) and central (P<0.01) areas of the 
retina (Figure 4.16). When compared to shams, there was also a significantly higher 
M/L-opsin+ cone density in the superior (P<0.001), peripheral (P<0.001) and central 
(P<0.01) areas of the retina in the 25 mW/cm2 group (Figure 4.16). The 100 mW/cm2 
group had significantly higher M/L-opsin+ cone densities compared to controls or shams 
in the periphery (P<0.001) and in the superior quadrant (P<0.001), but the protection in 
the centre did not reach significance (P=0.19, 100mW vs sham; P=0.31, 100mW vs 
controls) (Figure 4.16). When normalised (on a pairwise basis) to the control left eyes 
ice, the relative protection of M/L-opsin+ cones by 25 mW/cm2 PBM was greater in the 
centre and periphery but was not significant (P=0.79; Figure 4.17).  When normalised 
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(on a pairwise basis) to the control left eyes, the relative protection of M/L-opsin+ cones 
by 100 mW/cm2 PBM was greater in the periphery than the centre, but the difference did 
reach significance (P=0.79; Figure 4.17).  
  
 
Figure 4.14 Representative immunofluorescent photomicrographs of rd1 (P60) retinal 
wholemounts labelled with Anti-R/G opsin from the sham, 25 mW/cm2 and 100 
mW/cm2 groups. Images shown are from the central and peripheral portions of the 





Figure 4.15 Boxplot representation of mean M/L-opsin+ cone density at P60 for 
treatment groups: control, sham, 25 mW/cm2 and 100 mW/cm2. Results were analyzed 
with ANOVA with Tukeys’ multi-comparison test. ***P<0.001. Black stars against 







Figure 4.16 Boxplot representation of the spatial distribution of M/L-opsin+ cone 
density at P60 in the peripheral retina (A), central retina (B) and superior retina (C). 
Results were analyzed with ANOVA and post-Tukey’s comparison test. **P<0.01 
***P<0.001 Black stars against control, green stars against sham. Error bars 
represent 1.5 times the 1st and 3rd interquartile range. 
 
 
Figure 4.17 Column bar graph displaying comparative regional efficacy of M/L-
opsin+ cone neuroprotection at P60 as a percentage of control for central vs 





4.3.4 Effect of photobiomodulation on survival of cone segments at P60 
ML-opsin+ segments stained with greater fluorescent intensity than cell bodies (Figure 
4.18A). This permitted separate quantification of segments, which was achieved by 
adjusting the image threshold to isolate M/L-opsin+ segments. In contrast, S-opsin+ cone 
cell bodies and segments stained with approximately equal intensity (Figure 4.18B). 
Separate quantification of S-opsin+ segments from cone cell bodies could not be 
accurately attained using image thresholding. Hence, for quantification of separate cone 
segment densities only M/L-opsin+ segments were used, which necessarily represent 
both genuine ML-opsin+ cones and dual cones. 
 
At P60, the mean cone segment density was significantly higher in the 25 mW/cm2 
(P<0.001, n=8) and 100 mW/cm2 PBM-treated groups (P<0.01, n=9) when compared to 
controls (n=24) (Figure 4.19). When compared to shams (n=7), there was significantly 
higher neuroprotection in eyes treated with 25 mW/cm2 PBM (P<0.001), but not 100 
mW/cm2 PBM (P=0.17). There was, however, no statistical significance between the 25 
mW/cm2 and 100 mW/cm2 groups (P=0.14).  
 
Analysis of the distribution of M/L-opsin+ segments showed that there was a 
significantly higher density in the 25 mW/cm2 group compared to controls in the 
superior retina (P<0.01), central retina (P<0.05) and peripheral retina (P<0.05) (Figure 
4.20). The 25 mW/cm2 PBM group also showed significantly higher numbers of  M/L-
opsin+ segments than shams in all three regions analysed (P<0.05 - P<0.01). When 
normalised (on a pairwise basis) to the control left eyes, the 100 mW/cm2 PBM group 
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had significantly higher cone segment density in the superior (P<0.01), central (P<0.05) 
and peripheral (P<0.05) regions of the retina. Relative to the sham group, however, 
segment density did not reach significance in the superior (P=0.067), central (P=0.3) or 
peripheral regions (P=0.24). When normalised (on a pairwise basis) to the control left 
eyes, the relative preservation of segment density afforded by 25 mW/cm2 PBM (P=0.82) 
and 100 mW/cm2 PBM (P=0.74) was of a similar magnitude in the central and 





Figure 4.18 Representative images of M/L-opsin+ (A) and S-opsin+ (B) 
immunoreactivities (IR). Insets 1 and 2 are magnified views of two regions from each 
photomicrograph. (A) For M/L-opsin+, cell bodies stain lightly, but segments stain 
intensely (see insets). Thus, segments can be differentiated from cell bodies using 
image thresholding. The right panel shows the ML-opsin+ IR overlaid with the mask 
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derived from image thresholding (white represents areas to be quantified). It can be 
seen that the mask recapitulates the distribution of immunolabelled segments. (B) For 
S-opsin+, cell bodies and segments both stain intensely (see insets). Thus, segments 
cannot be routinely differentiated from cell bodies using image thresholding, as 
illustrated by the S-opsin+ IR overlaid with the mask derived from image thresholding. 
The mask does not recapitulate the distribution of immunolabelled segments. (C) 
Representative M/L-opsin+ IR photomicrographs (left), masks derived from image 
thresholding (centre), and M/L-opsin+ IRs overlaid with the mask (right), from the 
superior peripheral quadrants of two retinas, both of which feature substantial M/L-
opsin+ cone survival. It can be seen that the retina in the lower panel has much 







Figure 4.19 Boxplot representation of mean cone segment density at P60 for 
treatment groups: control, sham, 25 mW/cm2 and 100 mW/cm2. Results were analyzed 
with ANOVA with Tukey’s multi-comparison test. **P<0.01 ***P<0.001 Black stars 
against control, green stars against sham. Error bars represent 1.5 times the 1st and 






Figure 4.20 Boxplot representation of the spatial distribution of cone segments at P60 
in the peripheral retina (A), central retina (B) and superior retina (C). Results were 
analyzed with ANOVA and post-Tukey’s comparison test. Error bars represent 1.5 




Figure 4.21 Column bar graph displaying comparative regional efficacy of cone 
segment neuroprotection at P60 as a percentage of controls for central vs peripheral.  





4.3.5 Effect of photobiomodulation on survival of S-opsin+ cones at P90 
 
 
Figure 4.22 Representative immunofluorescent photomicrographs of rd1 (P90) retinal 
wholemounts labelled with OPNSW1 from the sham, 25 mW/cm2 and 100 mW/cm2 
groups. Images shown are from the central and peripheral quadrants of the retina. 
Scale bar: 100 µm. 
 
In order to ascertain whether the neuroprotective influence of PBM extended to longer 
durations, a small study was conducted in which PBM was administered until P90. This 
study featured only 8 mice, to which the left eye was left untreated, while the right eye 
received twice weekly PBM (100 mW/cm2) until P90. Compared to controls (n=8), 
there was significantly (P<0.001) higher mean survival of S-opsin+ cones in the PBM-
treated group (n=8) at P90 (Figure 4.22, 4.23). When analysed by distribution, the 
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neuroprotective effect of PBM was significant in the superior (P<0.05), inferior 
(P<0.01), and peripheral (P<0.001) regions of the retina, but the effect did not reach 
significance in the central (P=0.11) region (Figure 4.24). When normalised (on a 
pairwise basis) to the control left eyes, the extent of neuroprotection by PBM was 
greater in the superior compared to the inferior regions of the retina but was not 
statistically significant (P=0.20). When normalised (on a pairwise basis) to the control 
left eyes, PBM neuroprotection was similar in the central and peripheral (P=0.62) retina 





Figure 4.23 Boxplot representation of mean S-opsin+ cone density at P90. (A) mean 
S-opsin+ cone density following 100 mW/cm2 PBM at P90 compared to control and (B) 
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25 mW/cm2 PBM and 100 mW/cm2 PBM at P60._ Data of 100 mW/cm2 PBM and 
control at P90 were analyzed with paired t-test. Whiskers represent 1.5 times the 1st 




Figure 4.24 Boxplot representation of the spatial distribution of S-opsin+ cone density 
at P90 in the inferior (A), superior (B), peripheral (C) and central (D) regions. Results 
were analyzed with paired t-test. Whiskers represent 1.5 times the 1st and 3rd 





Figure 4.25 Column bar graph showing comparative regional efficacy of S-opsin+ 
neuroprotection with 100 mW/cm2 PBM expressed as percentage of control. Results 





4.3.6 Effect of photobiomodulation on survival of M/L-opsin+ cones at P90 
 
Figure 4.26 Representative immunofluorescent photomicrographs of rd1 (P90) retinal 
wholemounts labelled with Anti-R/G opsin from the sham, 25 mW/cm2 and 100 
mW/cm2 groups. Images shown are from the central and peripheral quadrants of the 
retina. Scale bar: 100 µm. 
 
Overall, there was significantly (P<0.001) greater M/L-opsin+ cone density in the PBM 
group compared to the control group (Figure 4.26, 4.27). When subdivided by area,  
M/L-opsin+ cone density in the PBM treated group was significantly greater in the 
periphery (P<0.01), the centre (P<0.05) and the superior quadrant of the retina (P<0.01) 
compared to controls (Figure 4.28). When normalised (on a pairwise basis) to the 
control left eyes, the relative preservation of M/L-opsin+ cone density by PBM was 
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greater in peripheral compared central regions magnitude but did not reach statistical 




Figure 4.27 Boxplot representation of mean M/L-opsin+ cone density at P90. (A) 
mean ML-opsin+ cone density following 100 mW/cm2PBM at P90 compared to control 
and (B) 25 mW/cm2 PBM and 100 mW/cm2 PBM at P60._  Data of 100 mW/cm2 and 
control at P90 were analyzed with paired t-test.  Error bars represent 1.5 times the 1st 






Figure 4.28 Boxplot representation of the spatial distribution of M/L-opsin+ cone 
density at P90 in the peripheral retina (A), central retina (B) and superior retina (C). 
Results were analyzed with ANOVA and post-Tukey’s comparison test. Whiskers 
represent 1.5 times the 1st and 3rd interquartile range. *P<0.05 **P<0.01  
 
 
Figure 4.29 Column bar graph showing comparative regional efficacy of M/L-opsin+ 
cone neuroprotection with 100 mW/cm2 PBM at P90 expressed as percentage of 
control. Results were analyzed with a paired t-test. Data represent mean±SEM. 





4.3.7 Effect of photobiomodulation on survival of cone segments at P90 
There was significantly (P<0.01) greater cone segment density in eyes treated with 100 
mW/cm2 PBM (n=8) compared to controls (n=8) at P90 (Figure 4.30). When analysed 
by distribution, cone segment density in PBM-treated eyes was greater in the peripheral 
(P<0.05) and central (P<0.01) retina (Figure 4.31).  The difference did not quite reach 
significant in the superior retina when analysed in isolation (P=0.093). When 
normalised (on a pairwise basis) to the control left eyes, the relative protection of cone 








Figure 4.30 Boxplot representation of mean cone segment density at P90. (A) mean 
ML-opsin+ OS density following 100 mW/cm2PBM at P90 compared to control and (B) 
25 mW/cm2 PBM and 100 mW/cm2 PBM at P60._  Data of 100 mW/cm2 and control at 
P90 were analyzed with paired t-test. Error bars represent 1.5 times the 1st and 3rd 





Figure 4.31 Boxplot representation of the spatial distribution of cone segment density 
at P90 in the peripheral (A), central (B) and superior (C) regions. Results were 
analyzed with paired t-test. Error bars represent 1.5 times the 1st and 3rd interquartile 
range. *P<0.05 **P<0.01  
 
 
Figure 4.32 Column bar graph showing comparative regional efficacy of cone 
segment neuroprotection with 100 mW/cm2 PBM at P90 expressed as percentage of 
control. Results were analyzed with a paired t-test. Data represent mean±SEM. 





4.3.8 Effect of photobiomodulation on optomotor performance at P35 
PBM significantly improved optomotor tracking performance, measured at P35, in eyes 
treated with 25 mW/cm2 (P<0.001, n=4) or 100 mW/cm2 (P<0.001, n=14) when 
compared to controls (n=21) (Figure 4.33). Similarly, there were significantly higher 
optomotor functions for the 25 mW/cm2 (P<0.01) and 100 mW/cm2 (P<0.05) groups 
when compared to shams (n=4). There was no significant difference between the 25 
mW/cm2 and 100 mW/cm2 groups (P=0.52). 
 
 
Figure 4.33 Column bar graph showing optokinetic (OKN) function of treatment 
groups at P35. Results were analyzed with ANOVA and Tukey’s multi-comparison 
test. Data represent mean±SEM.*P<0.05 **P<0.01 ***P<0.001 Black stars against 





The cause of secondary cone degeneration in RP is poorly understood. Several 
hypotheses including energy failure, oxidative stress, cone starvation and microglial 
activation have attempted to explain this phenomenon.224 PBM is known to increase 
mitochondrial membrane potential via COX as well as reduce oxidative stress and 
inflammation through retrograde signaling pathways. 137,147,148,163,164,190  Hence, PBM 
may be a novel therapy to prevent secondary cone degeneration in RP.  
 
The first part of the study was to characterize the cone population in the rd1 mouse 
retina at P60. While detailed information is available on the spatial distribution of 
genuine S-opsin cones, genuine M/L-opsin cones, and dual cones in the retinas of albino 
and pigmented mouse strains225, as well as albino and pigmented rat strains226, hitherto, 
relatively little has been published about the survival of the different cones types in the 
degenerating rd1 retina. Whilst there have been previous studies34,227,228 examining 
patterns of cone degeneration in the rd1 mouse, none of them have examined dual cones 
which comprises a significant portion of cone subtypes in our study. Such data would 
not only augment knowledge of the patterns of loss of the different cone types, but 
would provide valuable baseline data for the PBM neuroprotection study. To achieve 
this goal, retinal whole-mounts from untreated rd1 eyes were immunolabelled with 
antibodies to S- and M/L-opsins. The cone densities of genuine S-opsin cones, genuine 
M/L-opsin cones, and dual cones were then quantified in each of the four retinal 
quadrants. Overall, the mean cone population at P60 comprised 59.1% genuine S-opsin 
cones, 26.9% dual cones, and 14.0% M/L-opsin cones. There was a marked divergence 
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in cone composition between the superior and inferior retina. The superior retina at P60 
consisted of a majority of dual cones (53.67%), followed by genuine M/L-opsin cones 
(38.1%) and a sparse population of genuine S-opsin cones (8.23%). In contrast, the 
inferior retina at P60 contained almost exclusively genuine S- opsin cones (97.71%) 
with a small minority of dual cones (2.29%), and no identifiable genuine M/L-opsin 
cones. Nasal and temporal regions had similar compositions of genuine S-opsin cones 
(30.16%, 23.18%), genuine M/L-opsin cones (23.59%, 18.69%) and dual cones (46.25%, 
58.13%).  
 
The patterns of regional cone distribution found in the current study were similar, 
although not identical, to the distributions described in earlier characterization studies 
using normal pigmented and albino rodents.225,226 Thus, S-opsin+ cones tended to be 
more densely populated in the inferior-nasal regions and became sparser superiorly. 
Dual cones tended to be more densely populated in the superior nasal regions and 
became scarcer in the inferior regions. These were in agreement with our data. The 
results obtained herein showed S-opsin+ cones formed the majority of the cone 
population at P60 pan-retinally, which can be explained by the comparatively slower 
degeneration of S-opsin+ cones relative to M/L+ cones in rd1 mice.34 We did, however, 
find a greater number of S-opsin+ cones in the superior retina of P60 rd1 mice compared 
to those identified by Lin et al.227 The explanation underlying this difference is not 
immediately obvious, but may conceivably be related to the fact that different S-opsin 
antibodies were used in the two studies. Alternatively, it could simply represent a 
difference between the population of rd1 mice used in the present study to those used by 
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Lin et al. a decade ago. Nevertheless, our finding that an overwhelming proportion of 
cones in the inferior retina at P60 were S-opsin+ cones, and hence that there were 
correspondingly very few M/L-opsin+ cones, is consistent with the results of both Lavail 
et al228 and Lin et al.227   
 
In wild type pigmented and albino rats, M/L-opsin+ cones have a central-peripheral 
gradient with density greatest around the optic nerve,225,226  a pattern that differs from 
the superior-inferior gradient displayed in our rd1 mice. The simplest explanation for 
this apparent discrepancy is that M/L-opsin+ cones degenerate more rapidly in the 
inferior than the superior retina, and in the central compared to peripheral retina. This 
deduction is supported by the results of previous rd1 mouse characterization 
studies.34,227 Moreover, the data presented here represent a characterization of rd1 cone 
population at only one timepoint, P60, which will have evolved from earlier time points 
and will continue to evolve as cones continue to degenerate. We do have preliminary 
data characterizing the spatio-temporal distribution of S-opsin+ and M/L-opsin+ cone 
degeneration in the rd1 mouse at time-points up to P300 that augment the current 
data.229 At P7, S-opsin+ cones have the highest density in the inferior region and the 
lowest in the superior region. In contrast, M/L-opsin+ cones are uniformly distributed. S-
opsin+ and M/L-opsin+ cones degenerate in a hemispheric asymmetric fashion; S-opsin+ 
cone loss occurs faster in the superior regions, whilst M/L-opsin+ degenerates quicker in 
the inferior retina. At P300, only a sparse population of M/L-opsin+ cones remain in the 
peripheral inferior and nasal regions, whilst a limited number of S-opsin+ cones remain 
in the peripheral superior and nasal regions. Overall, the data from this characterization 
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study are particularly informative in terms of the neuroprotection study. In terms of 
characterizing the distribution of  genuine S-opsin, genuine M/L-opsin cones and dual 
cones in the rd1 retina, it will be important in the future to examine earlier time points, 
for example, P14 prior to commencement of cone degeneration, and P30, a time point 
relatively early in cone degeneration. Such data will inform about the relative survival of 
different cone populations in this animal model of RP and will prove useful in future 
studies that use the rd1 mouse model to examine cone loss and neuroprotection 
strategies.   
 
The second part of the present study assessed the neuroprotection efficacy of laser-
directed PBM on cone degeneration in the rd1 mouse. The primary outcomes were S-
opsin+ and M/L-opsin+ cone densities in whole-mount retinae. The secondary outcome 
was functional measurement of OKN.  The results showed significant neuroprotection of 
S-opsin+ and M/L-opsin+ cone cell bodies, as well as segments, at P60 in groups treated 
with 25 mW/cm2 or 100 mW/cm2 PBM, when compared to shams and untreated 
controls. In addition, PBM at 100mW/cm2 provided significant neuroprotection of S-
opsin+ and M/L-opsin+ cones compared to control eyes at P90. The histological 
protection of cones likely explains the finding that eyes treated with PBM at both 
irradiances also had significantly better OKN function when compared to control and 
sham eyes.  
 
The overall findings augment the published body of data showing the benefit of 670nm 
PBM in preclinical studies of photoreceptor protection in retinal degeneration 
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models.134,147,180,191-193 Eells et al.147 were the first to describe in-vivo photoreceptor 
protection by PBM. They used a rodent model of retinal methanol toxicity and showed 
that PBM preserved photoreceptor morphology on histopathology and significantly 
recovered rod- and cone-mediated ERG amplitudes. Abarracin et al. in several 
studies134,141,191 reported that PBM protected photoreceptors and visual function in light-
induced retinal injury and oxygen-induced degeneration. PBM treated retinal sections 
had significantly lower photoreceptor apoptosis marked by reduced TUNEL (dUTP nick 
end labelling) staining in the ONL, preserved retinal structures histologically, reduced 
stress markers and reduced oxidative stress. PBM prior to, or during, light-induced 
retinal injury resulted in preserved rod and M/L-opsin+ cone OS structures, as well as 
preserved cone opsin gene opn1mw. Moreover, eyes treated with PBM before and 
during light-induced retinal injury had higher photopic b-wave amplitude compared to 
untreated eyes, suggesting preservation of cone function. Subsequent studies of PBM in 
light-induced retinal injury have similarly described decreased photoreceptor apoptosis, 
ONL preservation, reduced oxidative stress and inflammatory markers.180,193. Whilst 
these studies utilized 670 nm LED with irradiances ranging from 18 mW/cm2 to 60 
mW/cm2, we report significant neuroprotection of cones and preservation of visual 
function with a 670nm laser with irradiances up to 100 mW/cm2 or 9 J/cm2 fluence 
which is within range of previous PBM studies.230,231 
 
The present study is the first to examine the neuroprotection efficacy of PBM on the rd1 
mouse. This strain is a well-defined autosomal recessive model of RP that is 
characterized by a PDE6B gene mutation resulting in rapid degeneration of rods by P8-
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10 and thinning of the ONL which is complete by P21. Progressive cone loss occurs 
subsequently with almost complete depletion by P300. Hence, there is a narrow 
therapeutic window in this rapidly progressive RP model. ERG was not deemed useful 
as the ERG signal in the rd1 mouse becomes absent at P21232, coinciding with initiation 
of PBM treatment. Similarly, SD-OCT was not considered valuable as most of the 
retinal thickness reduction had occurred by the initiation of treatment. OKN function is 
still measurable despite an absent ERG as remaining opsins in the inner segments can 
facilitate photopic vision.76   
 
The neuroprotective benefits of PBM are observable in rd1 mice as early as P35 
following 2 weeks of PBM, exhibited by OKN improvement, and persists to at least P90 
where there was still significant cone and segment survival. The mean cone survival in 
PBM treated eyes was generally lower at P90 compared to P60, suggesting PBM did not 
completely halt cone loss, rather significantly delaying it. Our results support findings 
from Eells et al.195 which examined PBM on the P23H-3 rat, a comparative RP rodent 
model that possesses a rhodopsin mutation similar to an autosomal dominant form of 
human RP. Daily delivery of 670 nm LED with 50 mW/cm2 irradiance or 4 J/cm2 
fluence was administered to P23H-3 pups during the critical period of photoreceptor 
development P16-20. Following treatment there was decreased photoreceptor apoptosis, 
increased retinal COX particularly in the photoreceptor inner segments, upregulation of 
antioxidant enzyme Mn-SOD and increased neurotropin CNTF.195It must be kept in 
mind that photoreceptor loss is considerably slower in P23H rats233 and at their 
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timepoints, no cone loss would have occurred. Hence, comparisons of neuroprotective 
efficacy against secondary cone loss is impossible to draw from Eells et al. 195 
 
Unlike previous PBM studies180,188,191 which examined photoreceptor protection 
predominantly with TUNEL staining of retinal sections, the use of double labelling 
immunofluorescence on wholemount retinae in our study allowed us to examine the 
efficacy of PBM on survival of cone subtypes throughout the retina. The use of 
OPN1SW and RG-opsin antibodies, which demarcate both cone cell bodies and 
segments, is preferable to peanut agglutinin, as the latter stains only cone outer/inner 
segments and hence is unable to stain surviving cone cell bodies, which persist long 
after segments have degenerated.227 
 
Our data suggest PBM confers protection to both cone subtypes up to P90. There was 
significantly greater neuroprotection efficacy at P60 in peripheral regions compared to 
central regions for both the 25 mW/cm2 and 100 mW/cm2 groups. One explanation for 
this finding is that cone degeneration occurs at a slower rate in the periphery than in 
central regions, hence there is greater scope for cone survival in the central retina.234. At 
P90, the peripheral versus central divergence was no longer observed for S-opsin, 
although a caveat is that “N” numbers were lower than at P60. Up to P90, both 25 
mW/cm2 and 100 mW/cm2 PBM conferred significant M/L-opsin+ cones in all regions. 
There was no significance regional difference in neuroprotective efficacy between PBM 




Whilst there was significant neuroprotection with both irradiation doses, there was a 
trend for greater protection of cones and their segments with 25 mW/cm2 PBM; although 
no significant differences in neuroprotective efficacy between the two irradiation doses 
was found on Tukey’s post-hoc test- a relatively conservative test. A statistical 
significance may be anticipated with a higher “N” number. With hindsight, therefore 
greater neuroprotective efficacy might have been expected with 25 mW/cm2 PBM at 
P90. Nonetheless, the data highlights a useful irradiance range of 25-100 mW/cm2 PBM 
laser for future photoreceptor neuroprotection studies. Further work is needed 
particularly on the rd1 mice and other models of RP to identify an “ideal” PBM 
irradiance dose. 
 
The observed significant neuroprotection in the treated eyes compared to the fellow 
control eye suggests PBM produces a localized effect, differing from other 
studies196,235,236 that suggest systemic benefits. On the other hand, Tang et al.144 reported 
localized improvement of non-central diabetic macular oedema in PBM treated eyes 
compared to the fellow control eyes of patients. We suspect this mechanism is 
dependent on the biomechanics of the targeted tissue and the delivery modality which 
impacts penetrance and any subsequent systemic effects.   
 
The neuroprotective mechanisms of PBM on rd1 mice were not explored in this study. 
Further elucidation will be needed in future studies. We have preliminary data 
demonstrating PBM pretreatment of mixed retinal cultures with 670nm PBM laser up to 
500 mW/cm2 irradiance protects against sodium azide induced mitochondrial inhibition, 
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highlighting potential mitochondrial protection and anti-oxidative mechanisms.237  
Investigating PBM’s impact on oxidative stress, mitochondrial function and microglial 
activation in rd1 mice would be an important step in addressing theories of secondary 
cone degeneration and validating PBM as a novel therapy for RP.  
Another limitation is that our study lacked quantitative analysis of outer segments. We 
used cone arrestin to qualitatively assess outer segments. We did not find any 
discernable differences in cone arrestin labelling away from the optic nerve between any 
of the treatment groups even in the affected 500 mW/cm2 however we do acknowledge 
quantitative analysis may provide a clearer insight on the effect of PBM on outer 
segments.   
4.5 Conclusion 
In conclusion, PBM significantly augmented S-opsin+ and ML-opsin+ cone survival in 
rd1 mice up to P90 and improved visual function as determined by OKN. Further 
studies are needed to elucidate the mechanisms to explain the observed PBM 








5. General discussion and conclusions 
5.1 Introduction 
Outer retinal degenerative diseases including RP or AMD are characterized by 
photoreceptor degeneration. It is believed that a deficiency in the supply of energy to the 
outer retina plays a crucial part in these conditions. It therefore seems logical to attempt 
therapeutic intervention in each case by utilising a bio-energetic approach.   
RP is an inherited retinal degenerative condition, but due to the quantity and 
heterogeneity of causative gene mutations, an effective treatment remains elusive. These 
gene defects initially cause the death of rod cells, but secondary cone death inevitably 
follows. Since abrogation of rod loss in RP is unlikely to be achieved in a clinical 
scenario without genetic intervention, then the understanding and prevention of cone 
degeneration represents the most clinically significant therapeutic target. Furthermore, 
prevention of cone loss would essentially prevent blindness in afflicted patients.  The 
quest for an understanding of secondary cone loss in RP has received much attention. 
Mechanistic explanations include oxidative stress, microglial activation, loss of rod-
derived survival factors and an increase in toxins derived from dying rods.224 More 
recently, the role of an energy deficiency in cones as a result of rod cell loss has also 
been implicated.34,35,119 If this were verified, it would suggest that a bio-energetic-based 
strategy may prevent or reduce cone loss in RP. 
PBM is a potential therapy in which red/near infrared light is applied non-invasively 
with the aim of protecting a tissue or alleviating the negative effects of a disease or toxic 
treatment. Mechanistically PBM has been proven to enhance mitochondrial functioning, 
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and thus, could represent an ideal candidate bioenergetics-based strategy for applying to 
cone preservation in RP. PBM has previously been shown to have some positive effects 
in different models of retinal degeneration or damage134,141,191 when applied via LED 
delivery. However when applied in this way there is necessarily an associated random 
scattering and filtering of light by the eye, thus, determining safe, acceptable dosages is 
practically difficult. With this in mind, the present body of work aimed to assess the 
safety of applying PBM directly to the retina via laser and, having established this, to 
determine its efficacy at providing protection to this t in a well-characterised model of 
degeneration. The model selected against which to test the neuroprotective efficacy of 
the PBM laser was the rd1 mouse, a rapidly progressive autosomal recessive RP model. 
5.2 Summary of findings 
The findings from the safety study in Chapter 3 reflect that PBM, as applied by laser, 
has a safety threshold of below 500 mW/cm2 irradiance or 45 J/cm2 fluence in 
pigmented rats. In rats exposed to PBM at an irradiance of 500 mW/cm2 but not 100 
mW/cm2, histological damage was observed to both the ONL and the RPE which was 
consistent with SD-OCT findings. These changes were obvious as early as 3 days 
following laser with more severe damage noted at 7 days post-laser by SD-OCT analysis. 
In agreement with this, on FA, fluorescein leakage was present in pigmented rats at 7 
days but not 3 days after PBM treatment with an irradiance of 500 mW/cm2. The 
presence of fluorescein leakage suggests vessel damage and the appearance of this 
leakage between 3 and 7 days post-treatment is reflective of evolving retinal 
degeneration. It is suspected that the damage is a reflection of photothermal laser injury 
or an oxidative damage corresponding to PBM’s biphasic dose response. There was no 
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functional retinal change in any of the rats, as reflected by scotopic ERG assessment, 
however, a multifocal ERG analysis would have been more sensitive than the system 
employed and therefore may have detected damage. As a comparison, albino rats were 
not adversely affected even at 500 mW/cm2 irradiance, again, suggesting a photothermal 
mechanism for damage in the pigmented animals, where melanin may have acted as an 
additional photoacceptor for the laser light. Overall, these results provided guidance for 
the appropriate irradiance levels of the PBM laser for the subsequent neuroprotection 
study. 
The second study, as described in Chapter 4, demonstrated that PBM, as applied by laser 
at irradiances of both 25 mW/cm2 and 100 mW/cm2 has a strong neuroprotective effect 
against cone degeneration in the rd1 mouse. This was observed as a significantly 
increased cone survival level at P60 and P90 as compared with both non-lasered or 
sham-lasered controls. The PBM laser treatment significantly protected ML-opsin and 
S-opsin cones throughout all regions of the rd1 retina at P60 but was less pronounced in 
certain regions at P90. Moreover, there was significant preservation of visual function in 
eyes treated with PBM as assessed by OKN analysis at P35. The significant 
neuroprotection in treated eyes compared to fellow control eyes also suggested that 
PBM provides a localized rather systemic effect. These findings form a strong 
foundation for future neuroprotective studies in other retinal degenerative models as 
well as in the clinical setting. 
5.3 Overall significance 
The safety study, described in Chapter 3, is the first to specifically define safe and 
optimal PBM treatment parameters on retinal tissue with use of a specially designed 670 
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nm laser. Although there have been previous safety studies applying PBM via laser to 
brain219 and hair222 to define treatment parameters, all tissues have a unique physiology 
and so such data are not necessarily appropriate for retinal treatment. Hence, the 
elucidation of the therapeutic limits for PBM laser in this study are extremely important 
for any future treatment of this tissue with a similar system. The presence of focal 
damage at high irradiance doses of 500 mW/cm2 in some pigmented rat retinae supports 
the existence of a definite safety threshold and an optimal effective irradiance, likely 
corresponding to the biphasic dose phenomenon observed and described in previous 
PBM studies186-188. Thus, when applied to the variably pigmented eyes of patients in the 
clinic, although the potential therapeutic range for the laser may be large, there are 
definite limits to treatment doses, above which retinal damage may be induced. 
The impressive findings from the neuroprotective study support previous studies of 
PBM as a viable therapy for retinal degenerative disease. Furthermore, this is the first 
study to demonstrate the capacity of PBM to protect cones in the genetic rd1 mouse 
which is typically considered a severe RP model with a narrow therapeutic window. The 
preservation of OKN function in PBM-treated eyes suggests preservation of functional 
OS which means that the treatment has significant benefits. A strategy to prevent cone 
degeneration in RP patients would essentially prevent blindness and would represent a 
major medical breakthrough. Hence, the present results provide a significant impetus for 
further studies assessing laser-delivered PBM in both laboratory-based and clinical 




There are several limitations to the safety study (Chapter 3). The first limitation is the 
limited time-points for assessment of changes. Additional assessments between day 3 
and 7 may allow closer observation of SD-OCT/histological changes and provide a clue 
to the evolution of detrimental effects. Furthermore, time-points beyond 7 days would 
offer a better longitudinal perspective on the safety of PBM.  Another limitation is the 
use of only three irradiance doses: 25 mW/cm2 (2.25 J/cm2 fluence), 100 mW/cm2 (9 
J/cm2 fluence) and 500 mW/cm2 (45 J/cm2 fluence), with a large range between them. 
Assessment of additional doses between 100 and 500 mW/cm2 may be helpful in 
narrowing the boundary between safe and destructive irradiances. In addition, when 
examining post-mortem tissue, histological examination of oxidative stress markers may 
have helped reveal the mechanisms of dose-related damage and defining, for example, 
whether tissue lesions were oxidative or photochemical in nature. As mentioned 
previously, a multifocal ERG would also have provided a greater measure of functional 
changes given the focal degree of damage observed in affected rats. 
The main limitation in the rd1 mouse study was that the mechanism of neuroprotection 
for PBM was not explored. It is believed that PBM provides its neuroprotective benefit 
through increasing mitochondrial function, reduction of oxidative stress and suppression 
of inflammation. Additionally, only the 100 mW/cm2 irradiance dose was examined at 




5.5 Future directions 
Subsequent experiments should highlight the mechanisms of PBM-derived 
neuroprotection observed within this body of work. Either purified cone cultures or 
mixed retinal cultures with a cone population can provide a useful in-vitro platform to 
examine neuroprotection efficacy of PBM against oxidative and metabolic insults.  At 
an in-vivo level, measurement of oxidative stress markers (acrolein, haemoxygenase-1, 
NADPH oxidase and 8-Hydroxy-2'- deoxyguanosine), COX expression, inflammatory 
markers (GFAP, C3, TNF-α), microglial activation (iba1, CD68), via techniques such as 
immunohistochemistry or Western blot would shed light on the mechanisms behind the 
significant cone neuroprotection observed in this study. 
The use of alternative RP rodent models with slower photoreceptor degeneration 
including S334ter-3 rats and rd10 mice would allow longer therapeutic windows to 
observe cone neuroprotection. This would permit the use of ERG and SD-OCT as useful 
adjunctive in-vivo measurements of cone function and structure.  
Further experiments examining the variation of dose frequency and duration of effect 
may also provide useful data for clinical translation. Given the fact that the laser device 
is mounted on a slit-lamp with a similar arrangement to current lasers in the ophthalmic 
clinic, it means that a PBM laser such as the one used in the present study requires 
minimal training for clinicians. This therefore potentially allows for immediate clinical 
translation. Finally, the results from this present work have created an incentive for a 
phase 1 clinical trial of PBM on RP patients. Such a pilot study will examine the safety 
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